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Lung cancer is the cancer responsible for the most deaths worldwide. Treatment is 
multimodal and based on information specific to the tumor (histology, stage, biology and 
genetics aberrations) and patient-related factors. During the last decade, the arrival of novel 
targeted therapies and immunotherapy, has led to a paradigm shift in the management of lung 
cancer. In this regard, assessment of tumor immunology is of great interest to researchers and 
clinicians.  
 
The immune system undoubtedly plays an important role in the progression and development 
of cancer. Although it is just a snap-shot picture, it is established that the local immune status, 
at the time of resection, can provide important prognostic information and influence the 
clinical management and survival of cancer patients. Currently, the most prominent examples, 
where immune cell assessment are clinically relevant, are colorectal and breast cancer.  
 
The immune infiltrate comprises adaptive and innate immune cell subsets in which 
lymphocytes, macrophages and neutrophils are the major populations orchestrating tumor 
immunity. Advancing the understanding of immune infiltration has significant potential for 
the development of clinical prognostic and predictive immune markers for patients with 
NSCLC. The ultimate goal in studying the in situ immunity of NSCLC is to apply this 
information for optimization of immunomodulation and immunotherapy.  
 
The present study was designed to study tumor-infiltrating lymphocytes, macrophages and 
neutrophils, which seems to represent a potential powerful prognostic instrument for NSCLC. 
In addition, this thesis emphasizes the importance of the choice of methodology for reliable 
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1.1 Lung cancer 
1.1.1 Epidemiology 
 
Global: Lung cancer is the leading cause for cancer-related deaths worldwide. Approximately 
2.1 million persons will be diagnosed with lung cancer in 2018, accounting for almost 12% of 
all cancer patients [1]. In men, lung cancer is both the most common cancer and cause of 
cancer-specific mortality. In women, lung cancer is the fourth most common cancer and the 
second highest cause of cancer-specific mortality [2]. The incidence of lung cancer is mainly 
driven by exposure to cigarette smoking. In the 1920s and1960s, the incidence started to raise 
for men and women, respectively, elucidating the earlier uptake of smoking in males. Initially 
smoking was adapted throughout society, regardless of socioeconomic status. However, 
equivocal evidence of the link between smoking and lung cancer, and other smoking related 
diseases, has led to a socioeconomic gap where those with higher education and income are 
more likely not to start or to cease smoking [3]. Currently, developed countries have 5-7 folds 
higher incidence of lung cancer compared to developing countries. However, declining 
smoking rates in the western world is already started to reflect in lung cancer incidence and, 
as of now Central and Eastern Europe along with Eastern Asia has the highest incidence rate 
in males, while North America and Europe have the highest incidence rates in females [4]. In 
the coming decades the incidence of lung cancer will likely fall in developed countries and 
rise in developing countries.  
 
Norway: The latest report of cancer statistics by the Norwegian National Cancer Registry [5] 
shows that lung cancer is the second most common cancer in men (after prostate cancer) and 
the third most common in women (after breast and colon cancer; Figure 1). In total, lung 
cancer has the highest mortality rate and constituted 19.8% of all cancer related deaths in 
2016. For women, the incidence of lung cancer was 9% higher in the period of 2012-2016 
compared to 2007-2011, exhibiting a consistent increase since the 1950s. In men, the 
incidence of lung cancer showed a further 6% decline, consistent with a leveling off during 
the last two decades [5]. Interestingly, overall survival of lung cancer patients has improved 




Figure 1: Incidence trends for selected cancers in Norway from 1958 to 2017 (age-standardized; adopted from 
Norwegian National Cancer Registry, Cancer in Norway 2017) [5]. 
 
 
1.1.2 Risk factors 
 
Among all cancers, the most well-known environmental factor causing cancer is tobacco 
consumption. Tobacco exposure from smoking cigarettes, cigars and pipes is considered the 
primary cause of 87% of lung-cancer cases [7]. In the early 20th century, lung cancer was a 
rare disease. However, the incidence and mortality rates increased sharply when smoking 
became epidemic [8]. Duration and amount of consumed tobacco is a powerful determinant of 
lung cancer risk. Besides lung cancer, cigarette smoking is also an important cause of cancer 
in head & neck, pancreas, bladder, stomach, liver and kidney [9].  
Cigarette smoke contain about 60 carcinogenic substances, and their carcinogenicity have 
been proven by several animal models and experimental studies [10]. Passive smoking, called 
second-hand smoke, is also associated with a greater risk of lung cancer. A lifelong exposure 
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to second-hand smoke (smokers at home or workplace), 16-30% increases the life-time risk of 
lung cancer for nonsmokers [9].  
 
Long-term occupational or residential exposure to ionizing radiation/radon or chemical 
compounds, including asbestos, chromium, silica, polycyclic aromatic hydrocarbons and 
diesel exhaust, are considered risk factors [11]. Lung cancer in non-smokers is more common 
in females and in East Asia, and has been associated with environmental exposures including 
passive smoking, pollution, occupational carcinogens and inherited genetic susceptibility 
[12]. For instance, indoor air pollution (burning coal for cooking and heating) and exposure to 
cooking oil vapors, are considered risk factors, particularly in Asian women [13].  
 
In addition to environmental factors, age and inheritable factors are associated to lung cancer. 
Incidence is higher in the older population, with a median age of 70 for both smokers and 
non-smokers [14]. Polymorphisms and variations in chromosomal region 15q24-25.1 [15], 
DNA repair genes [16] and epidermal growth factor receptor (EGFR) T790M gene [17] 
increases the risk of lung cancer. 
 
1.1.3 Histological classification 
 
In general, lung cancer can be classified into two pathologically distinct main groups: non-
small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). The current histological 
and immunohistochemical criteria for the classification of lung cancer is based on the World 
Health Organization (WHO) guidelines, 4th version, announced in 2015 (Appendix 1) [18]. In 
brief comparison to the 2004 WHO classification, the following major points were 
highlighted in latest edition: use of immunohistochemistry for classification; molecular tests 
for managing advanced stages; reclassification of adenocarcinoma (ADC) and squamous cell 
carcinoma (SCC) subgroups [18,19].  
  
SCLC is a highly aggressive neuroendocrine malignancy comprising nearly 15% of lung 
cancer cases. Initially, SCLC was believed to originate from the lymphatic system due to its  
morphological resemblance to lymphoma [20]. SCLCs typically derive from peribronchial 
tissues. Clinically, when compared to NSCLC, SCLC generally present more aggressive 
behavior, high initial response to chemotherapy, and an earlier development of distant 
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metastases [21]. In difficult cases and small biopsies, immunohistochemical staining is 
applied to differentiate SCLC from NSCLC. Almost 90% of SCLCs are positive for thyroid 
transcription factor-1 (TTF-1) and neuroendocrine markers such as CD56, chromogranin-A 
and synaptophysin. Staining for cytokeratins and epithelial membrane markers are used to 
differentiate SCLCs from lymphoma and subsets of small round cell tumors [22]. 
 
The majority, approximately 85%, of lung cancer patients are histologically classified as 
NSCLC. NSCLC can be further subclassified by pathological characteristics into two major 
groups: ADC and SCC. For NSCLC patients in advanced stages, therapeutic decisions are 
heavily dependent on histological subtype and molecular properties [23].  
 
SCCs are characterized by squamous differentiation with intercellular bridges, individual cell 
keratinization and squamous pearl formation [24]. They arise from the bronchial epithelium 
of the proximal airways and are thought to progress through a series of preinvasive neoplastic 
lesions from squamous metaplasia, to squamous dysplasia (mild, moderate and severe) and 
finally into carcinoma in situ (CIS) [18]. SCC is largely associated with a history of smoking 
and chronic inflammation [25]. Classically, SCC was the most common subtype of NSCLC, 
but during the recent decades a shift towards ADC has been observed. This alteration is 
believed due to changes in the carcinogenic substances and the introduction of cigarette filters 
[26]. The routine tests for differentiation between SCC and ADC are: p40 and p63 [27]. 
 
ADCs are histologically characterized by the presence of glandular differentiation and/or 
mucin production. They are thought to arise from the alveolar or bronchial epithelium 
(pneumocytes or club cells) of distal airways and mostly arise in the peripheral parts of the 
lung [28]. The 2015 WHO classification further categorize invasive adenocarcinoma based on 
the dominant growth pattern into solid, papillary, micropapillary, acinar and lepidic subtypes. 
Recent reclassification has unified terminology and diagnostic criteria, and consequently the 
terms bronchioloalveolar carcinoma (BAC) and mixed adenocarcinoma are obsolete. In 
addition, the term minimally invasive adenocarcinoma (MIA) was recommended to define 
small lepidic tumors (≤ 3cm) with an invasive component ≤ 5mm [18,29]. 
  
Large cell carcinoma (LCC), which constitute < 5% of lung cancers, is a less common 
subtype of NSCLC [30]. LCCs do not exhibit squamous or glandular morphology. Although 
LCC and SCLC exhibit some similarities, such as positivity for neural markers, they can be 
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distinctly separated. Immunohistochemical markers for LCC identification are TTF-1 and/or 
cytokertain-1, -5, -10, -14 and -20. Almost 50% of LCCs express TTF-1, while they to a 
lesser extent express epithelial cytokeratin markers [31]. As the diagnosis of LCC is based on 
ruling out ADC, SCC and SCLC, diagnostic accuracy is significantly improved when resected 
specimens are available instead of biopsies [18,28].  
 
1.1.4 Diagnosis and staging 
 
Most lung cancer patients are diagnosed in advance stages of their disease. Probably because 
clinical signs are varied or missing and patients can be asymptomatic for a long time. Typical 
symptoms of a primary tumor in the chest is cough, dyspnea and/or hemoptysis. The 
clinically suspected lung cancer patient will undergo radiology with thoracic x-ray and/or 
computed tomography (CT) scan. CT is more sensitive and specific than x-ray which have 
relatively poor resolution and accuracy. Other imaging tools, such as magnetic resonance 
imaging (MRI) or positron emission-tomography-CT (PET-CT), can be utilized in addition to 
CT or plain x-ray [32,33]. 
 
Although imaging studies are noninvasive and provide valuable information, tissue evaluation 
remains the gold standard for a confirmatory diagnosis. A broad range of techniques are 
available for tissue sampling and staging purposes, including conventional or navigational 
bronchoscopy, endobronchial ultrasound needle aspiration (EBUS-NA), endoscopic 
ultrasound needle aspiration (EUS-NA), combined EBUS/EUS, transthoracic needle 
aspiration (TTNA), transbronchial needle aspiration (TBNA) and sputum cytology [34]. 
 
Following clinical assessment, imaging studies and tissue diagnosis, malignant lung tumors 
are clinically staged according to the updated 8th edition of the Union for International Cancer 
Control (UICC) TNM classification (Appendix 2) [35]. The purpose of TNM staging is to 
provide a description of the extent of cancer at the time of diagnosis based on information of 
three parameters: Size and growth pattern of the primary tumor (T), involvement of regional 
lymph nodes (N) and distal metastasis (M). The TNM model has been designed based on the 
experience and clinical outcomes of groups of previous patients with similar stage. TNM 
staging serve as a prognostic indicator and assists clinicians in treatment decisions. The main 
differences between the two latest TNM models (7th vs 8th version) are: 1) T category have 
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been subdivided further by size; 2) N category, no change; 3) M category, distinguishes single 
versus multiple extrathoracic metastasis [35,36]. 
Notably, there are some important prognostic features, such as vascular infiltration and 
surgical margins, that are not included in the TNM classification model and needs to be 
considered separately [37]. 
 
1.1.5 Molecular diagnosis 
 
Molecular testing of genetic alterations has become a valuable approach to guide therapeutic-
specific decision-making in advanced NSCLC. The diagnostic molecular tests detect three 
classes of genomic alterations: mutations, translocations and amplifications [38]. The rapid 
development and availability of next-generation sequencing (NGS) platforms, has 
significantly changed the molecular diagnostic practice. NGS enables simultaneous 
assessment of several target genes in a single test with high sensitivity and specificity. 
 
In NSCLC, the first discovery of targetable oncogenic aberrations was mutations in the 
tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) in 2004 [39]. 
Currently, EGFR mutation analyses are well-established and are the most widely used 
predictive molecular markers in NSCLC. The most frequent hotspots, where EGFR 
alterations occur, are deletions in exon 19 (45% of EGFR positive patients) and missense 
mutation at exon 21 codon 858 (40% of EGFR positive patients). Almost 75% of patients 
harboring EGFR alterations experience tumor regression and improved survival by the use of 
TK inhibitors (TKI) like erlotinib, gefitinib and afatinib [40].  
 
Other predictive molecular biomarkers in this context are anaplastic lymphoma kinase (ALK) 
and ROS proto-oncogene 1 (ROS1). Approximately 2-7% of all NSCLC patients have 
translocations in encoding-genes of ALK. Patients carrying ALK translocations are EGFR-
TKI resistant, while their clinical characteristics are the same as EGFR-mutated patients [41]. 
Translocation of the ROS1 gene occur in 1–2 % of NSCLC patients. Patients positive for 





With the advent of immunotherapy, the expression status of programmed death ligand-1 (PD-
L1) in tumor and immune cells have become important tests to select patients for immune-
check point inhibitors in NSCLC. 
 
Briefly, according to the latest (May.2017) National Comprehensive Cancer Network 
(NCCN) and American Society of Clinical Oncology (ASCO) guidelines, the following 
molecular tests should be performed for all ADC NSCLCs, regardless of their clinical 
characteristics: 1) EGFR mutation analysis (at least for exon 19 deletion and exon 21 point 
mutation); 2) ALK translocation analysis by immunohistochemistry (IHC), fluorescence in 
situ hybridization (FISH) or NGS; 3) ROS1 translocation analysis by FISH or NGS; 4) B-Raf 
proto-oncogene (BRAF) V600E mutation analysis; and 5) PD-L1 expression analysis by IHC 
[43,44] (Figure 2). However, currently there is not any approved in vitro diagnostic test for 
ROS1 and BRAF, hence the clinicians should use well-validated assays to study ROS1 and 
BRAF. 
 
Broader NGS panels can detect a range of alterations in tumors related to either oncogenic or 
tumor suppressor genes including p53, KRAS, MET, ERBB2, RET, STK11, FGFR1 and 
others. This additional molecular data on patients’ samples could be beneficial for clinical 
decisions. For instance assessing tumor mutation load, derived either from large targeted or 
whole exome NGS panels, may predict response to immunotherapy [45]. 
However, these large DNA and RNA panels are not implemented in the routine clinical 
setting and their use should be limited to clinical trials [46].  
 
In the near future, circulating tumor DNA (ctDNA) may provide a noninvasive and easy test 
for cancer diagnosis, prognosis and treatment-guidance. When fully established, the use of 
ctDNA for molecular evaluation (e.g., EGFR mutation) can be a potential alternative to 





Figure 2. Diagnostic Algorithm for NSCLC 
The upper portion of the algorithm shows the morphological classification of NSCLC based on histological 
(hematoxylin and eosin) and cytological (Giemsa) evaluation. The middle portion of the algorithm shows the 
molecular analysis for the key treatable oncogenic alterations: EGFR and BRAF V600E mutations and ALK and 
ROS1 translocations, as well as additional molecular analyses in selected patients. The lower portion of the 
algorithm shows the assessment of programmed death ligand 1 (PD-L1) expression by means of 






1.1.6 Treatment and prognosis of NSCLC 
 
Several factors, such as clinical staging, histological classification, molecular tumor features, 
Eastern Cooperative Oncology Group (ECOG) or Karnofsky performance status, age and so 
forth are influencing the choice of treatment for lung cancer patients. The optimal 
management of NCSCL requires careful evaluation of these factors in order to maximize the 
safety and efficiency of treatment. 
 
Surgical resection is the standard of care for NSCLC stage I and II. Expected 5-year survival 
is 73-90% for pathological stage I and 56-65% for stage II. Risk assessment of patients 
eligibility for surgical resection is conducted in accordance with recommended guidelines 
[35,47]. Different types of surgical approaches are available according to size and localization 
of the tumor: pneumonectomy, lobectomy, segmentectomy or wedge resection. Lobectomy 
with systematic lymphadenectomy has been the conventional standard procedure and 
accounts for the majority of surgical cases (60-70%). In stage I, minimally invasive 
lobectomy such as video-assisted thoracoscopic surgery (VATS) lobectomy may be preferred 
to thoracotomy with respect to combined outcome and patient´s quality of life [48]. No 
survival benefit has been shown for adjuvant chemotherapy in stage I [49]. For stage I 
patients deemed not to be candidates for lobectomy or segmentectomy, stereotactic body 
radiation therapy (SBRT) or surgical wedge resection may be considered [50]. In this group, 
SBRT may improve 3 year survival rate from 25-35% to approximately 50%, with low rates 
of local failure, and moderate treatment toxicity [51]. Platinum-based adjuvant chemotherapy 
is recommended for patients (ECOG:0-1) with completely resected pathological stage IIA and 
IIB (N1) [50] .  
 
Stage IIIA NSCLC is the most challenging group for clinicians as the optimal treatment for 
this group remains unknown. If feasible, surgery should be performed. Expected 5-year 
survival in this group is 41% [35,52]. For patients not eligible for surgery, the standard of care 
is concurrent platinum-based chemoradiotherapy with a curative purpose for patients (N2 and 
N3; ECOG:0-1). The optimal radiation dose for concurrently treated patients is typically 60 to 
70 Gy [52]. In patients with completely resected NSCLC, adjuvant chemotherapy is 
recommended in T1-2, N1-2, M0 tumors, and tumors >4 cm. Adjuvant chemotherapy confers 
more benefits in stage IIIA. The 5-year survival of patients who had surgery plus adjuvant 
chemotherapy versus single modality-surgery were 39% vs 26% [53]. In addition, adjuvant 
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radiotherapy is a proper choice to reduce the incidence of local recurrence in patients with 
occult pathological N2 or R1 resection, but it is still unclear whether it improves survival 
[52]. 
 
Stage IIIB-IV patients are generally managed without surgery. In this patient group, the 
individual patient’s performance status has major impact on treatment selection and survival. 
Median survival is 12-19 and 6-11 months for clinical stage IIIB and IV respectively [35,46]. 
Classically, a doublet chemotherapeutic regime of platinum-based compounds (carboplatin or 
cisplatin) and third-generation chemotherapy agents (paclitaxel, docetaxel, gemcitabine, 
pemetrexed or vinorelbine) is the standard of care. Alternatively, the platinum-based doublet 
may be combined with angiogenesis inhibitors (bevacizumab), which leads to a modest 
improvement of both overall- and progression free survival (PFS) in non-SCC NSCLC 
patients [54,55].  
 
Recent evidence supports that the choice of first line therapy for advanced NSCLC should be 
based on molecular profiling. Utilizing this approach, many patients will be selected for 
targeted therapies or immunotherapy [37]. In patients with sensitizing EGFR mutations, first-
line therapy with an EGFR TKI is recommended due to prolonged response rates, progression 
free survival and favorable toxicity profiles compared to standard platinum-based 
chemotherapy. In patients with ALK or ROS1 translocations, receiving ALK inhibitors (such 
as crizotinib, ceritinib or alectinib), showed superior response rate, progression-free survival 
(PFS), and quality of life when compared to standard chemotherapy [46]. 
 
Currently, there are two clinically FDA-approved immune check-point inhibitors for lung 
cancer: anti-PD1(nivolumab) and anti-PDL1(pembrolizumab). Nivolumab is recommended as 
subsequent therapy in patients with metastatic non-SCC or SCC NSCLCs (>1% PDL1 
expression), who has progressed during or after first line chemotherapy. For ALK/ROS1- 





1.2 Tumor immunity 
1.2.1 Tumor immune microenvironment 
 
A tumor is a product of developing interactions between various cell types both within the 
tumor and the surrounding tumor microenvironment (TME) or stroma. The tumor stroma 
consists of extracellular matrix and various cell types such as immune cells, fibroblasts, 
endothelial cells, pericytes, adipocytes and others [58]. In recent years, in the dawn of 
immunotherapy, assessment of the tumor immune microenvironment (TIME) has become an 
interesting biological and clinical consideration. The cellular components of TIME consist of 
lymphocytes (T and B cells) responsible for adaptive immunity, myeloid cells (macrophages, 
dendritic cells, neutrophils and mast cells) that participate in both the innate and adaptive 
immunity and other stromal cells [59]. Communication between these cells are either by 
juxtacrine or paracrine mechanisms involving inflammatory cytokine networks. The 
localization, density, functional orientation as well as expression of immune derived-
mediators and modulators of TIME have principal roles in directing tumor-associated 
inflammation toward tumor development or regression. In addition to the regulatory role of 
tumor-derived cytokines, chemokines, and growth factors, the mutational profile (particularly 
encoding-genes that create neoantigens) of the cancer cells can impact on the subset and 
amount of immune infiltration in stroma [60].  
 
1.2.2 Innate and adaptive response 
 
Innate response: The immune system protects the body from disease through two interrelated 
arms, the innate (natural) and adaptive immunity. Innate immunity involves a large number of 
different cell populations mainly derived from the myeloid lineage. These include, but are not 
limited to, monocytes, macrophages, granulocytes (neutrophils, eosinophils and basophils), 
dendritic cells, and natural killer cells (from the lymphoid lineage). Innate immune cells 
generally arise from hematopoietic stem cells in the bone marrow. The fist-line defense 
against pathogens relies on the activation of these cells. They recognize pathogens (or stress-
associated and damage-associated molecular patterns) through different classes of pattern 
recognition receptors (PRRs). After recognition, the innate cells react against perturbing 
pathogens through general processes such as phagocytosis, complement cascade activation, 
and induction of inflammation. The inflammation process mainly occur due to the release of 
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soluble inflammatory mediators (cytokines, extracellular matrix remodeling enzymes and 
ROS) and bioactive mediators (e.g., histamine) by activated cells, which induce recruitment 
and infiltration of additional immune cells into damaged tissue [61].  
 
Neutrophils, and to some extent eosinophils, are first recruited to the site of acute 
inflammation. They eliminate pathogens directly by releasing toxins and through 
phagocytosis. The second wave of cells are monocytes, which differentiate to macrophages 
within the tissue. Activated macrophages are an important source of cytokines and growth 
factors profoundly affecting tissue structure. Mast cells can also release pro-inflammatory 
effectors such as cytokines, proteases, and histamine. In acute inflammation, both mast cells 
and macrophages affect epithelial and vascular endothelial cell function, important for 
elimination of pathogen and initiation of tissue repair processes. Basophils (subclass of 
granulocytes) are functionally close to mast cells, and their primary role is to secrete 
histamine which induces inflammation by increasing blood flow to the inflamed site [62]. 
 
Natural killer (NK) cells are important lymphoid-derived components of the innate immune 
system. NK cells defend the host from pathogens by direct cytotoxic attack on their targets or 
by producing a large array of mediators (importantly IFN-γ). The released inflammatory 
mediators contribute to initiation of the antigen-specific immune response. NK cells also 
participate in cellular crosstalk between innate and adaptive immune cells through 
bidirectional interaction with dendritic cells (DCs) [63].  
 
DCs are part of the antigen-presenting cells system that initiate and modulate the adaptive 
immunity. These act as sentinel cells that basically monitor the microenvironment for danger 
signals (damage-associated molecular patterns). Activation of DCs depend on the local 
proinflammatory effectors milieu and pathogenic antigens. DCs undergo a maturation phase 
after capturing the foreign pathogen and migrating to lymphoid organs, where they present 
antigen peptides in association with major histocompatibility complex (MHC) to naive CD8 
(by MHC class I) and CD4 (by MHC class II) positive T-cells [64].  
 
Adaptive response: Acute activation of innate immunity sets the stage for induction of the 
more tailored adaptive immune system. Adaptive immunity is a specific response to a 
particular antigen mainly driven by two leukocyte subsets, B and T cells. This defense system 
functions explicitly by a somatic rearrangement process in lymphoblasts, to produce a huge 
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number of antigen receptors such as T-cell receptors (TCRs) and/or immunoglobulin-based B 
cell receptors (BCRs). When T-cells are activated, they initiate the adaptive immunity in three 
ways: 1) direct attack on antigen-bearing cells by cytotoxic T lymphocytes (CD8+ T-cells), 2) 
stimulation of B lymphocytes to generate specific antibodies against the antigens, and 3) 
boosting the innate response and thereby inducing inflammation at the site of antigen 
engagement [62,65]. 
  
B-cells constitute a subpopulation of lymphocytes which express various cell surface 
immunoglobulin receptors recognizing specific antigenic epitopes. The majority of B-cells 
reside within lymphoid follicles, where they face and interact with T-cell-specific antigens 
bound to follicular DCs, proliferate, and either differentiate into plasma cells or memory B- 
cells [66]. After activation, selected B- and T-lymphocytes undergo clonal expansion after 
presentation and recognition of foreign particles, to obtain sufficient antigen-specific B- and 
T-cells for eliminating pathogens. Hence, the responsiveness of the primary adaptive 
immunity is slower than the innate system. However, during primary adaptive responses a 
subpopulation of lymphocytes differentiate into memory T- or B-cells, resulting in more 
robust responses after subsequent recurrence of the same antigen. Together, the innate and 
adaptive immunity cooperate during host defense to eliminate pathogens and restore tissue 
homeostasis. When expressed inappropriately or subjected to long-term involvement (chronic 
inflammation such as viral hepatitis infections), immune cells can give rise to autoimmune 
diseases or cancer, respectively [67]. 
 
1.2.3 Cancer immunoediting 
 
The inverse tumor-promoting and tumor-inhibiting effects of the immune system, have 
resulted in the hypothesis of cancer immunoediting. The theory of cancer immunoediting 
underlines that extrinsic immune mechanisms may either prevent tumor progression or 
promote tumor growth by inhibition of host antitumoral immune responses. Cancer 
immunoediting (also named ´ the three E’s`) relies on three steps: elimination (previously 
known as cancer immunosurveillance), equilibrium (persistence) and immune escape 
(progression) [68]. 
 
Elimination: The elimination of malignant tumors may occur at an early stage. Such a process 
consists of four phases: (i) Tumor antigens are recognized by innate cells which partially 
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remove the tumor cells. ECM remodeling due to tumor progression, induce pro-inflammatory 
signals resulting in recruitment of additional innate immune cells (including macrophages, 
DCs, NK cells, natural killer- and γδ-T lymphocytes) to the tumor site [69]. (ii) Interferon Is 
and γ limits tumor growth via initiation of interferon-dependent processes with 
antiproliferative, antiangiogenic and proapoptotic effects [69,70]. (iii) Recruited DCs activate 
after exposure to cytokines or interaction with NK cells. Then, the activated (mature) DCs 
migrate to lymph nodes, where they promote activation of T-helper (CD4+) cells and tumor 
antigen-specific CD8+ T-cells. (iv) In the last step, in order to complete elimination of tumor, 
the activated CD4+ and CD8+ T-cells of the adaptive system contribute in killing the antigen-
specific tumor cells via direct and indirect (ex. IFN-γ-dependent) mechanisms [68]. 
 
Equilibrium: In Equilibrium, the immune system holds the residential cancer cells in a state of 
functional dormancy which is clinically undetectable. Equilibrium is the longest of the three 
phases and may last several years in humans [68]. Compared to elimination and escape, less 
detail is available about equilibrium as it is difficult to model this state of immunity in 
animals. Specific components of the adaptive immune system, including CD8+ and CD4+ T-
cells (and not innate cellular components), are thought to be responsible for keeping the 
occult tumor cells in equilibrium. At this point there is probably a balance between 
antitumoral (e.g., INF- γ and interlukin-12) and protumoral cytokines (e.g., interleukin 10 and 
23) [71].  
 
Escape: At this step, nascent tumors are fully immunoedited and the immune control fails to 
restrict their progression. Hence, the cancer become clinically apparent. The tumor cell escape 
process can occur through diverse mechanisms such as: (i) absence or reduced immune 
recognition due to loss of tumor-antigenicity or MHC expression, (ii) deficiency in apoptotic 
signaling pathways and activation of anti-apoptotic signals including overexpression of 
STAT3 and BCL2, or (iii) development of an immunosuppressive milieu through the effect of 
immunosuppressive mediators (e.g., IL-10, TGF-β and VEGF) and immune cells (e.g., 
(myeloid-derived suppressor cells and regulatory T-cells) or immunoregulatory molecules 






Further support for cancer immunoediting can be found in reports correlating the quantity of 
tumor-infiltrating lymphocytes (TILs) with favorable clinical outcome [73]. These findings 
imply that TILs are effective at postponing tumor development. However, it is important to 
consider that different TILs have distinct functions in the TME. Cytotoxic CD8+ TILs, are 
capable of killing cancer cells directly [65]. CD8+ regulatory T cells (Tregs) possess an 
immunoinhibitory function and are able to maintain immune homeostasis via CXCL4 [74]. 
However, their role in cancer is poorly understood. CD4+ TILs are a heterogeneous class of 
cytokine secreting lymphocytes, comprising several distinct subpopulations. For cancer, the 
Th1, Th2, Th17, and Treg CD4+ TILs are deemed the most important [75]. Th1 cells produce 
IFN-γ and IL-2 which mediates activation of CD8+ TILs. Th2 cells produce a broader range 
of cytokines (e.g., IL-4, IL-5, IL-9, IL-10, IL-13, IL-25) and limit CD8+ TIL proliferation. In 
terms of antitumoral responses, Th2 activation is less effective than Th1 activation (Table 1). 
Th17 cells secrete IL-17 and mediate induction of many organ-specific autoimmune diseases. 
CD4+ Tregs secrete IL-10 and TGF-b, which maintains self-tolerance through the 
suppression of effector TILs [76,77]. Overall, immune infiltration of various adaptive 
lymphocyte subsets has been associated with improved prognosis in many different cancers 
[73,78]. 
 
Table 1. Innate and adaptive immune cells involved in regulating tumor growth in human 
Stimulate Cancer growth Inhibit cancer growth 
Innate Immune cells  
Neutrophils Dendritic Cells* 
Macrophages (M2) Macrophages (M1) 
Myeloid derived suppressor cells  
Adaptive immune cells  
TH2 CD4+ T cell Cytotoxic CD8+ T cell 
CD4+ T regulatory cell TH1 CD4+ T cell 
B lymphocytes* TH17 CD4+ T cell 
Abbreviation: Th, T helper 
*Have been associated with both stimulation and inhibition. 
Reproduced with permission from American Society of Clinical Oncology [77]. 
 
In NSCLC, extensive stromal infiltration by CD8+ or CD3+ TILs is strongly associated with 
patient survival [79–81]. No conclusive results has been achieved on the prognostic impact of 
CD4+ TILs [82]. However, among the CD4+ TIL subsets, Th1 cells have been associated 
with improved survival [83], while Th2 cells were associated with tumor progression [84]. 
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High levels of Th17 CD4+ TILs have been associated with lymphangiogenesis and a poor 
clinical outcome [85]. Notably, CD45RO+ T-cells are other subclasses of TILs, considered as 
memory T lymphocytes. Overexpression of CD45RO+ TILs has been associated with 
improved outcomes in various cancers as well as NSCLC [86]. FOXP3 is a key regulatory 
transcription factor for the development and function of Tregs. High infiltration of 
FOXP3+Tregs has been correlated with poor survival in NSCLC [87,88]. In contrast to T-
cells, the precise prognostic impact of B-cells and plasma cells are currently not well defined 
and remains controversial [80]. Until now, the most robust prognostic TIL marker in NSCLC, 
is CD8 [89]. 
 
Immunohistochemistry is the optimal method to evaluate TIL subsets. Nevertheless, several 
studies have investigated total TIL levels using standard hematoxylin and eosin (H&E) 
staining and found strong prognostic and predictive impact [60,90]. Initially, assessment of 
TIL levels in breast cancer H&E slides was reported as a powerful predictor of response to 
neoadjuvant chemotherapy [91]. Since then, several studies in various cancers have evaluated 
H&E TILs [60]. In 2014, Salgado et al (in collaboration with a panel of international 
pathology experts) recommended a standardized guideline for evaluating H&E TILs in breast 
cancer [92]. A general update of this guideline, for many solid tumors, was proposed by 
Hendry et al [93]. In NSCLC, a couple of studies have evaluated TILs in H&E routine slides 
with various scoring models [94–98]. However, no consensus for the evaluation of TILs in 
H&E for NSCLC have been reached. The original breast cancer H&E TILs assessment 
guideline is an attractive choice for adaptation, but requires comprehensive validation for 




In addition to TILs, the cellular composition of the TME contains various types of immune 
cells including neutrophils, macrophages, mast cells, DCs, and NK cells. Tumor-associated 
neutrophils (TANs) constitute a significant portion of the TME and are the most prevalent 
immune cell type found in lung cancer [99,100]. In humans, it is still unclear whether the 
presence of TANs stimulate or suppress tumor growth. Based on studies in murine models, it 
has been proposed that TANs polarize into either a N1 antitumoral or N2 protumoral 
phenotype [101]. TANs are recruited to target sites by local overexpression of chemokine 
receptors including CXCR1 and CXCR2. Tumor cells and associated mesenchymal cells 
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express various ligands (e.g., CXCL1, CXCL2 and CXCL5) that accelerates recruitment of 
TANs [102]. 
  
N2—pro-tumor role: In various cancer models, TANs were found to facilitate cancer cell 
extravasation via a number of direct and indirect mechanisms. Neutrophils and other 
inflammatory cells capable of remodeling ECM have long been considered mediators of 
cancer cell invasion and metastasis through surface expression of selectins and integrins 
(adhesion receptors) or production of neutrophil extracellular traps (NETs) [103,104]. TANs 
release granules containing neutrophil elastase, matrix metalloproteinase-8 (MMP8), MMP9 
and proinflammatory cytokines, which degrade ECM and facilitate tumor progression [104]. 
MMP-9, in contribution with CXCL8, activates VEGF-A and FGF2 and initiates angiogenesis 
[105]. Hepatocyte growth factor (HGF) is a pleotropic cytokine with angiogenic attributes. 
TANs may produce HGF following exposure to local pro-inflammatory mediators, which 
promote invasion and metastasis of tumor cells [106]. ROS (generated by NADPH oxidase of 
phagolysosomes), produced by neutrophils is a powerful defense against pathogens. In 
malignancy, however, ROS may exert both genotoxic effects by initiating tumor proliferation 
and DNA damage, or conversely, cytotoxic effects mediating tumor suppression [107]. 
 
N1—anti-tumor role: In addition to the broad literature on their protumoral impact, there is 
also evidence of antitumoral activity mediated by TANs. In the original study [101], which 
proposed distinct N1 and N2 TAN subsets,  N1 TANs were described as cells generating a 
broad specter of cytokines, which were highly cytotoxic to tumor cells. Depletion of the N1 
antitumor TANs decreased CD8+ T-cell activity and led to increased tumor burden [101]. In 
addition, TANs may exert antitumor activity by directly killing tumor cells, or by producing 
factors leading to recruitment and activation of innate and adaptive immune cells. In early 
stage cancer, TANs induce T-cell responses and release proinflammatory cytokines (e.g., 




Figure 3: Neutrophils in cancer 
Neutrophils influence the tumor environment and cancer progression through multiple mechanisms. At the 
primary tumor site (left box), activated neutrophils can induce genetic damage or signaling in pretumoral cells 
through reactive oxygen species (ROS), reactive nitrogen species (RNS), and proteases, thereby promoting 
tumorigenesis (Initiation). In primary tumors, neutrophils can prevent tumor progression by activating cytotoxic 
immunity or nitric oxide (NO) production. As the tumor progresses, neutrophils become predominantly 
protumorigenic: transfer of elastase (NE) activates proliferation within tumor cells; arginase-1 (ARG1) suppresses 
CD8+ T cell and NK cell responses; and release of MMP9 activates VEGF-A and FGF2 to support angiogenesis. As 
the tumor grows, cancer cells and the supporting stroma produce tumor-supporting factors: macrophages 
release IL-1β that induces IL-17 production by intratumoral γδ T cells, resulting in G-CSF-dependent expansion 
and recruitment of protumoral neutrophils from the bone marrow or the spleen; TGF-β programs immune 
competent neutrophils (N1) toward an immunosuppressive (N2) state. Neutrophils also influence tumor 
metastasis in negative and positive ways (right box). Production of hydrogen peroxide (H2O2) is toxic for 
metastatic cells. In contrast, capture of circulating cancer cells through neutrophil-derived Mac-1 or NETs favors 
their entry into tissues; and inhibition of natural killer (NK) and T cell responses supports the survival of 
metastatic cells, whose proliferation is additionally favored by neutrophil-derived leukotrienes. Reproduced with 
permission from Elsevier [102]. 
 
The prognostic significance of the innate immune cells is controversial and appears best 
studied within the context of individual tumor types. For TANs, high tissue infiltration was 
associated with a poor prognosis in kidney, esophagus and head & neck cancers [109–111], 
and with a good prognosis in gastric and colorectal cancers [112,113]. In NSCLC, previous 
studies have failed to reveal significant associations between TAN and patient survival 
[114,115]. The reasons behind varying outcomes are not clear, but may be related to the type 
of cancer, stage and histology. Until now, there are no specific markers available for 
differentiation between N1 and N2 phenotypes in human tissues. In published studies, CD66b 
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(alternative names: carcinoembryonic antigen-related cell adhesion molecule-8 or 
CEACAM8, NCA-95 and CD67), which is localized in human neutrophil and eosinophil 




Macrophages are a heterogeneous population of mononuclear phagocytic leukocytes. Their 
functions are specialized for the anatomical location in which they reside. Tissue 
macrophages derive from two main sources: Yolk sac and bone marrow progenitor cells. 
Dependent on tissue type, some tissues are populated by yolk sac-derived macrophages like 
Langerhans cells and microglia in the skin and brain, while, other tissues are populated by 
macrophages from bone marrow (circulating monocytes) [118]. Most macrophages involved 
in pathogenic responses, especially cancer, appear to originate from circulating monocytes 
[119]. The macrophages involved in cancer-initiated inflammatory responses are often named 
tumor-associated macrophages (TAMs). TAMs are a significant component of the myeloid-
derived infiltrate in tumor stroma, and studies of TAMs formed the basis for the models 
proposing that inflammatory infiltrates are involved in tumor development. Similar to TANs, 
a binary phenotype with distinct divergent functions were defined for TAMs: M1 antitumoral 
and M2 protumoral. TAM differentiation, growth, and chemotaxis is regulated by local 
cytokines and growth factors such as GM-CSF, MCSF, IL-3, CCL-2 etc [120]. 
 
M1—anti-tumor role: Th1 cytokines (IFN-γ and TNF-α) are the key players when 
macrophages polarize into the M1 phenotype. M1 macrophages typically: (I) overexpress 
proinflammatory cytokines such as IL-12, IL-23 and TNF; (ii) express MHC class II and 
costimulatory molecules such as those in the B7 family; (iii) express CXCL9 and CXCL10 to 
amplify Th1 responses; (iv) underexpress IL-10. Functionally, M1 macrophages contribute to 
the host defense mechanisms through activation of NADPH and production of ROS. This 
process is mainly regulated by the sustained production of IFNg secreted by Th1 cells. As 
described for TANs, ROS produced by TAMs may lead to both progression and regression of 
tumors. The M1 phenotype is vital to the initial antitumoral defense and their activation is 
partly regulated by the anti-inflammatory activity of M2 subpopulations—to protect against 




M2—pro-tumor role: Similar to the M1—Th1 axis, M2 polarization is significantly 
influenced by Th2 cytokines. M2 macrophages can be further subclassified into M2a, M2b, 
M2c, and M2d according to different environmental signals. M2 TAMs produce high levels 
of IL-10 and express scavenger receptors, mannose receptors, IL-1 decoy receptor and 
hyaluronan receptor LYVE-1 [123]. In general, M2 TAMs promote tumor growth and 
dissemination through ECM remodeling, angiogenesis, immunoregulation and 
immunosuppression [124]. M2 TAMs, typically present at hypoxic areas in tumor stroma and 
induce proangiogenic factors such as VEGFs and PDGFs via overexpression of HIF-1a. M2s 
are the major source of enzymes and proteases (e.g., MMPs, plasmin, osteonectin, and 
cathepsins) that regulate the degradation of surrounding ECM, thereby allowing tumor cells to 
spread and metastasize [125,126]. Different direct and indirect mechanisms allow M2 TAMs 
to inhibit anti-tumor Th1-mediated adaptive immunity. In direct (cell-to-cell) mechanisms, 
M1 TAM´s surface receptors/ligands interact with their counterpart´s inhibitory 
receptors/ligands of target immune effector cells. For example, M2 TAMs possess the ligand 
for PD-1 and CTLA-4 immune checkpoints that upon activation inhibit the cytotoxic activity 
of CD8+ T-cells, NK and NKT cells. Through indirect signaling, IL-10 secretion by TAMs 
may suppress the cytotoxic activity of CD8+T-cells and induce the regulatory activity of 
Tregs [122].  
 
In addition, macrophages may polarize into an 'M2-like' phenotype, which shares, but do not 
express all the signature properties of M2 macrophages. Antigen-antibody complexes, 
together with TGF-β and IL-10 can induce macrophage differentiation into the M2-like 
subsets which have shared features of IL-4/IL-13 activated cells, such as overexpression of 
mannose receptors, IL-10 and angiogenic markers. Different in vivo and transcriptome 
studies, in both normal and cancerous tissue, have confirmed different scenarios for M2 




Figure 4: The orchestration of macrophage activation and polarization by lymphoid cells 
(a) M1-polarized macrophages and their crosstalk with TH1 and NK cells. (b) M2 polarization of macrophages 
driven by TH2 cells, basophils and innate lymphoid cells through their secretion of IL-4, IL-13 or IL-33. (c) M2-like 
macrophages polarized by interaction with Treg cells. (d) M2-like polarization of macrophages by interaction 
with B cells through antibody-mediated FcγR activation or cytokines. FR, folate receptor; GR, galactose receptor; 
IFN-γR, IFN-γ receptor; IL-1decoyR, IL-1 decoy receptor; MHCII, major histocompatibility complex class II; MP, 
macrophage; MR, mannose receptor; SR, scavenging receptor; ST2, receptor; PGE2, prostaglandin E2; PTX3, 
pentraxin 3; RNI, reactive nitrogen intermediate; ROI, reactive oxygen intermediate. Reproduced with 
permission from Springer Nature [124]. 
 
In accordance to the protumor and antitumor mechanistic properties of TAMs, discrepant 
results exist concerning their prognostic significance. In some human tumors, an increased 
frequency of TAMs have been associated with poor prognosis, as shown in breast, head and 
neck, ovarian, gastric and bladder carcinomas, while in others, such as colorectal carcinoma, 
TAMs seem to convey a favorable prognosis [128]. In NSCLC, the prognostic impact of 




1.2.7 Tumor immune profile 
 
For most cancers, state-of-the-art prediction of clinical outcome is achieved by utilizing the 
TNM classification. However, outcome may vary among patients within the same TNM 
stage. Hence there is room for additional prognostic information to be considered beyond the 
TNM grading system [36,130]. The tumor immune contexture (defined as type, density, and 
location of immune cells) has demonstrated impact on clinical outcome [60].  
In colorectal cancer (CRC), a large body of evidence has revealed a tight correlation between 
the immune contexture status and patient survival [131,132]. Evaluation of CD8, CD3, 
CD45RO and granzyme B positive immune cells in different tumor compartments (invasive 
margin and tumor core), has added to the TNM staging system for CRC and given the name 
TNM-Immunoscore® (TNM-I). The TNM-I classifier is an easy model applicable for use in a 
routine practice through scoring the quantity (scoring range: I0-I4) of established immune 
markers in specified tumor areas. E.g., a low quantity of markers in both invasive margin and 
tumor cores scores “I0” whereas a high quantity of markers in both areas scores “I4” 
[133,134].  
 
In breast cancer, data obtained from large-scale studies have revealed the prognostic and 
potential predictive effect of TILs for both HER2 positive and triple negative patients. The 
clinical benefit of evaluating TIL in breast cancer is linked to models predicting the 
usefulness of pre-and post-operative chemotherapy and immunotherapy [135]. As discussed 
in Section 1.2.4, recommendations for an assessment of TILs have been proposed by an 
international breast cancer TILs working group, which endorses H&E staining and 
morphological evaluation of TILs for their proposed immunoscore [90,92]. 
 
In NSCLC, similar models have been proposed as complements to the TNM classification 
[89]. Various immune cell populations such as CD8, CD45RO, PD1, PD-L1, CTLA-4 and 
LAG-3, have been explored [79,86,136–138]. Until now, the most promising candidates are 
CD8 and CD45RO (SCC subgroup) [79,86,89]. In this context, there is clearly a potential to 
explore further immune-related markers for establishing a prognostically conclusive immune 





2 Aim of thesis 
 
The general aim of this thesis was to explore the in situ presence of the most prevalent 
immune cell subsets (neutrophil, macrophages and lymphocytes) in NSCLC. And further 







I. To explore associations between tumor-associated neutrophils and clinical outcome in 
histological subtypes of NSCLC. 
 
II. To validate H&E TILs assessment guidelines, originally proposed for breast cancer, in 
order to study its prognostic relevance in NSCLC whole-tissue section slides. 
 
III. To apply a reliable technical approach for identification of tumor-associated 
macrophage phenotypes in NSCLC, and to analyze their relationship with survival and 




3 Materials and methods 
3.1 Patient cohort 
 
Primary tumor: Formalin fixed paraffin embedded (FFPE) blocks were collected from 
consecutive stage I-III NSCLC patients who underwent radical resection at the University 
Hospital of North Norway (Tromsø) or the Nordland Central Hospital (Bodø) from 1990 to 
2010. Of a total of 633 primary tumor samples, 536 (in study I), 537 (in study II) and 553 (in 
study III) were included in the analyses. An overview of the of the cohorts is given in Table 
2. 
Exclusion criteria were as follows: i) Patients having malignancies other than lung cancer 
within five years of diagnosis (n=39, not including superficial skin cancer) as they are likely 
to either have received treatment that may alter the host immune response, experience 
relapses or harbor mutations making them susceptible to cancer, all of which may obscure 
statistical analyses; ii) Patients who received neoadjuvant chemo- and/or radiotherapy (n=15) 
as neoadjuvant treatment may alter the local host immune reaction via modifications in 
stroma immune cell composition; iii) Patients with in-adequate tissue in FFPE blocks (n=26); 
iv) Patients with H&E samples of poor quality (n=16 in study II). 
 
Lymph nodes: From the 633 surgically resected primary tumor samples, 172 patients were 
diagnosed with lymph node metastasis (LN+). Of 172 patients, 143 had adequate tissue for 
expression analysis and this LN+ cohort was included in study I and III. The details of both 




Table 2: A glance overview of the cohorts and applied methods 
 Primary tumor cohort LN+ cohort 
 Study I Study II Study III Study I Study III 
Tumor type NSCLC NSCLC NSCLC NSCLC NSCLC 




(633/536) (633/537) (633/553) (172/142) (172/143) 
Histological  
classification 
WHO 2004 WHO 2015 WHO 2015 WHO 2004 WHO 2015 
SCC 289 298 307 74 78 
ADC 201 232 239 58 65 
Other 46 7 7 10 - 










pStage       
I 256 226 232 - - 
II 194 181 185 70 59 











Clinical endpoints DSS, DFS, OS DSS, DFS, OS DSS DSS DSS 
Abbreviations: NSCLC, non-small cell lung cancer; LN+, node metastases; FFPE, formalin fixed paraffin 
embedded; WHO, world health organization; SCC, squamous cell carcinoma; ADC, adenocarcinoma; 
UICC, The Union for International Cancer Control; pStage, pathological stage; TMA, tissue microarray; 
mIHC, multiplex immunohistochemistry; H&E, hematoxylin and eosin; DSS, disease-specific survival; 
DFS, disease-free survival; OS, overall survival. 
 
Pros and cons: Significant strengths of the cohort is the large number of patients, the lack of 
patient selection, and, since all patients were recruited from two local hospitals, the reliable 
clinical data. Major considerations include the study’s retrospective nature and the long 
inclusion period.  
Retrospective studies are cost-benefit and time-saving compared to prospective studies, but 
have more potential for bias and cofounder effects. Besides, there may be lack of homogenous 
data and standardized follow-up. Other drawbacks include limited access to further 
demographic data about patients’ lifestyle and concomitant diseases.  
The patients in this study were included over a period of 20 years. During this period 
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guidelines for diagnosis and treatment (especially after implementation of adjuvant therapy in 
2005) of lung cancer have changed. To partly compensate for this, the cohort has been 
updated according to the latest guidelines for TNM- and histological-classifications. Updating 
the cohort will lead to a few patients changing overall stage. In some cases, patients will 
change to a stage where the treatment they originally received might not be considered 
appropriate according to current treatment strategies. This is exemplified by 21 patients being 
classified as stage IIIB after reclassification from the 7th to the 8th edition of the UICC 
guidelines. Moreover, improvements in imaging techniques during the inclusion period are 
significant. For example, many of the patients with occult N2 nodes included in the cohort 
would likely have been discovered by PET imaging and deemed not to be candidates for 
surgical resection. 
 
3.2 Clinical data 
 
The demographic and clinical data were retrieved from medical journals by an oncologist. In 
all three studies, the records included follow-up data until October 2013. The median follow-
up of survivors was 86 (range 34–267) months. In study I, the TNM staging was conducted 
according to the 7th edition of UICC guidelines [36] and the histological classification was in 
accordance to 2004 WHO guidelines [19]. However, in study II and III, the patients were 
restaged and the tissue specimens reclassified based on the latest UICC (2016) and WHO 
(2015) guidelines [18,35]. Notably, after histological transition from the 2004 to 2015 
version, previously excluded patients histologically classified as bronchioloalveolar 
carcinoma (BAC), were re-classified and re-included in the ADC subgroup of the cohort. The 
major difference in TNM staging after the transition from the 7th to the 8th version, was that 
21 patients were staged as IIIB. The reporting of clinicopathological variables, survival data 
and biomarker expressions was conducted in accordance with the REMARK (Reporting 
Recommendations for Tumor Marker Prognostic Studies) guidelines [140]. One major 
limitation with our database was lack of molecular alteration information for patients such as 
EGFR, ALK, KRAS and ROS1.  
 
Clinical endpoints: Disease-specific survival (DSS), disease-free survival (DFS) and overall 
survival (OS) are the clinical endpoints measured in our cohort. DSS was calculated from 
time of surgical treatment to lung cancer death. DFS was defined from time of surgery to first 
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relapse. OS defined the time between surgery and death of any cause. The time of death was 
retrieved from death certificates. 
 
The primary endpoint was DSS. DSS may be considered more sophisticated compared to 
other endpoints. As death by other causes is disregarded, DSS may potentially provide better 
data about the underlying biology. However, differentiating endpoints is difficult and requires 
comprehensive information about the cause of death. In the current cohort, the official cause 
of death was cross-referenced to the information available in the patient’s journal both in the 
regional and local hospitals and in cases with missing information, the patient’s general 
physician was contacted. These steps ensure high confidence in the clinical endpoints. 
Nevertheless, the cause of death was interpreted subjectively and potential differences in 
interrater variability was not tested. Therefore, it is possible that some few patients may 
change endpoints if a full revision, by separate investigators, was performed. Because of this 
latter argument, many researchers consider OS a more robust endpoint. In the studies included 




The initial database and cohort (involving 335 patients) was approved by the Regional 
Committee for Medical and Health Research Ethics (REK Nord) and the Norwegian data 
protection authority (DPA). In the latest ethical reapproval for the updated cohort with Id.no: 
2011/2503, the informed consent from patients was considered. Since this project was a 
retrospective study and most of the patients were deceased, the need for patients’ consent was 
waived by the boards of DPA and REK Nord. All patient’s personal data were anonymized 
prior to database entry.  
 
3.4 Tissue microarray 
 
Tissue microarray (TMA) is a cost-effective and time-saving technique suitable for large-
scale tissue-based studies and beneficial in order to preserve the tissue. A broad range of 
techniques, to evaluate DNA, RNA and/or proteins, utilizing immunohistochemistry and in 
situ hybridization principles, are compatible with TMAs. The staining or probing variability is 
greatly decreased when using TMAs, as large numbers of tissue samples are processed 
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simultaneously in consistent experimental conditions [141,142]. Each TMA block consist of 
several cylindrical cores sampled from different FFPE tumor/tissue blocks, arrayed in a single 
recipient paraffin block. The area of interest in each donor block has been marked by a 
pathologist, on the corresponding H&E slides. This area is then punched and transferred to a 
recipient block. Depending on the purpose of use, various tissues/compartments can be 
selected for transfer into recipient TMA blocks, such as tumor epithelial, normal- or tumor-
associated stroma, normal tissue, invasive margins and etc. The diameter of cores may vary 
from 0.6 to 1mm and the depth is normally 3mm [142,143]. 
 
The common concern regarding the use of TMAs is whether the small core samples arranged 
in recipient TMA blocks represent the whole heterogenous “face” of the tumor, especially 
when the donor specimen is rather large. For biomarker evaluations, a significant number of 
cores from donor blocks is essential for statistical considerations, primarily to reduce the bias 
associated to tumor heterogeneity. For the studies presented in this thesis, four to five cores 
from each patient were transferred to the recipient blocks, consisting of two cores from tumor 
epithelial, two from tumor-associated stroma, and one from normal alveolar tissue (if 
present). Besides, in both study I and III, a random comparison of 20 patients was performed 
between TMA cores and paired whole tissue slides, in which a correlation >95 % was 
observed. However, an interesting recent study in breast cancer evaluated the number of TMA 
cores required for a reliable assessment of lymphocytic infiltration. This study found that four 
cores represents a good trade-off between performance and the amount of tissue required. 
However, six cores were needed to achieve consistent prognostic value in the HER2 subgroup 
[144]. 
 
Other issues with TMAs include that they are not validated for routine clinical use and that 
some cores may detach and be missing from the TMA slides during the IHC or ISH procedure 









Immunostaining is commonly utilized to detect diagnostic, prognostic and predictive 
biomarkers. Among different immunostaining approaches, IHC offers a broad range of 
research and diagnostic applications for detection and visualization of proteins in tissues 
through labelling of antibodies, either direct or indirect antigen binding. In the clinic, IHC is 
an important ancillary tool in order to differentiate histology and diagnose different cancer 
types. In research, IHC is an essential technique for biomarker discovery. Identifying novel 
molecular or immunotherapeutic targets and developing personalized therapy has emerged a 
successful approach to improve patient’s outcome and care. IHC is a well-established and 
affordable technique, appropriate to complement TMA in order to deliver rapid and high 
throughput assessment in large-scale studies. Its ability to be applied for fresh frozen or 
formalin fixed specimens makes it highly practical, as specimens of these natures are the 
mainstay of most surgical pathology centers worldwide. It is a remarkably sensitive and 
specific approach when the proper antibodies and reagents are thoroughly chosen following 
prior validation on known tissue or staining controls [145]. 
 
While IHC is a powerful laboratory technique, it has certain limitations related to technical 
reproducibility. The technical issues are mostly derived from the preanalytical and analytical 
phases. Preanalytical variables are variation on tissue processing, fixation methods, and 
storage time prior to the analytical phase [146]. It is known that prolonged fixation in 
formalin may decrease the immunoreactivity of antibody/antigen in FFPE sections [147]. Due 
to the retrospective nature of this thesis, the findings may have been affected by the variables 
related to the preanalytical phases, particularly with respect to uncertainty regarding fixation 
time. However, the recent developments in antigen retrieval steps (within the analytical 
phase) has improved the unmasking of antigen significantly; even in samples with longer 
exposure to tissue fixatives [148]. Fixation duration varies depending on tissue type and size. 
The penetration time for formalin is longer in large resections and highly cellular dense 
tissues. Potential differences may occur when central versus peripheral parts of the tissue 
undergo such analyses, due to quicker fixation of the area of tumor at the periphery [149]. In 
the presented analyses, the quality of all patient specimens was verified and re-checked by 
two experienced pulmonary pathologists, and poorly qualified tissue was excluded.  
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Storage time may be an issue for IHC. However, in a study of antigenicity, up to 68 years of 
archiving FFPE blocks did not significantly impact IHC staining quality for most markers 
[150]. However, prolonged storing of sectioned slides impacts staining immunoreactivity. 
Due to this, all IHC procedures for the studies (study I and II) in this thesis were performed 
in fresh cut sections. Moreover, no significant differences in staining intensities and 
distributions were observed, when comparing patient samples collected before and after year 
2000 in the present cohort. 
 
However, there has been a surge of novel technologies for IHC, including automation, 
multiplexing, and digital pathology; which may overcome some of IHC’s inherent drawbacks. 
The development of automated platforms for tissue processing, fixation and performing IHC 
staining have directed laboratories closer to the goal of standardization and have improved 
technical reproducibility. The current IHC-autostainers vary significantly in their design and 
capabilities. Regarding analytical variables, utilizing autostainers provides uniform 
standardized microenvironments which results in higher intra- and inter-laboratory 
consistency and reproducibility. Besides labor saving, less hands, and reduction in manual 
variations, the main advantage of autostainers is providing stable temperature condition for 
antigen unmasking and enzymatic reaction [151]. The IHC assays included in this thesis were 
performed with one of the most advanced available platforms: Discovery-Ultra (Ventana, 
Roche). Discovery-Ultra is an open-system with high flexibility to run double IHC/ISH and 
chromogenic/ fluorescence multiplexing. The disadvantage of automated IHC-systems is that 




To better understand the complex expression pattern of biomarkers, IHC applications are 
shifting from single- towards multi-antigen detection. Multiplex IHC (mIHC) provides greater 
insights into tumors as well as helping to conserve tissue via simultaneous visualization of a 
larger number of markers. Chromogen-based mIHC is preferable when less than three 
markers are of interest. Fluorescence-based mIHC is more practical when assessing a large 
panel of markers [152]. Staining is either simultaneous (cocktail) or sequential. In 
simultaneous IHC, the antibodies are used to label antigens in one staining process. The 
cocktail method is useful for double labeling in which the two primary antibodies should be 
from different host species. Sequential IHC involves several iterations of labeling single 
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antigens, each with a different label or secondary antibody type (e.g., IgM vs IgG) until all 
desired antigens are visualized [153]. In our automated setting, the sequential strategy was 
employed (Figure 5). 
 
Figure 5. Sequential Multiplex IHC.  
Schematic model to represent the principal of 3-plex staining performed in paper I. Brown, purple and yellow 
chromogens were loaded to identify target cells. Between each sequence, two different approaches were used 
in order to denature the excess antibodies including: heat-induced denaturation and enzyme inhibitors. 
  
Drawbacks of mIHC include antibody cross-reactivity and chromogen overlap [154]. Cross 
reaction may occur between incomplete eluted antibodies and newly applied antibodies in 
each staining sequence. To overcome this hinder, enzymatic inhibition and heat-induced 
denaturation between each sequence (prior to loading the 2nd or 3rd primary antibody) were 
applied. Both the duration of enzymatic inhibition and the temperature were validated and 
verified in single-IHC to ensure that the structural integrity of the antigen was retained.  
 
The most common reporter enzymes for chromogenic labelling are: Horseradish peroxidase 
(HRP) and alkaline phosphatase (AP). Enzymes can be conjugated with different chromogens 
to produce a colored precipitate at the site of the antigen/antibody reaction. Cross-reactivity 
can be avoided or reduced by using separate HRP and AP conjugates [155]. Therefore, 
wherever mIHC was applied in this thesis, different conjugated chromogens were utilized 
(paper I: HRP—HRP—AP; paper III: HRP—AP). 
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Chromogens: Chromogens are molecules that allow detection of a target using enzyme-based 
precipitation reactions. For microscopical evaluation of mIHC, the chromogen combination is 
critical because visual contrast is the key requirement [154]. 
 
mIHC works best for the visualization of different tissue elements without colocalization.  
However, visualizing colocalized elements in a single cellular compartment, although 
challenging, is possible. Light shades overshadowed by darker shades or heavier dyes (e.g., 
DAB) can obstruct the visualization of colocalized or cellularly labelled antigens [156]. Thus, 
for visual assessment, careful selection of chromogens is required. In the history of IHC, 
many different chromogen combinations have been proposed for multiplexing. However, only 
a few have proven suitable for manual observation of mixed color at the sites of 
colocalization using bright-filed microscopy [157]. In recent years, the development of new 
and improved chromogen- and fluorescent-based detection systems have significantly 
expanded the application of immunolabelling. For instance, translucent chromogens, in 
conjunction with other chromogens, allows for detection of signal colocalization, via 
formation of a tertiary color. In study I and III, yellow was used as a landmark marker to 
stain the epithelial compartment without interfering with other chromogens. In study III, in 
order to visual assessment of colocalized signals, yellow in combination with teal created 
tertiary green color, which was easily distinguishable even with unaided eyes. Notably, the 
majority of previous studies based on chromogenic-IHC was performed using DAB as 
chromogen. In our setting, DAB in combination with any other chromogens (e.g., purple, teal, 
yellow, green, blue or red), was not a reliable choice for assessing colocalized markers, 
because the dominant brown color significantly obstructed the other dyes.  
 
However, similar to the necessity of technical adjustments (on dilution, temperature, antigen 
unmasking) in IHC protocols, chromogens have their own sensitivity and efficiency 




Antibodies have a broad range of applications in research, diagnostic and therapeutics. Two 
classes of antibodies are available: polyclonal and monoclonal. Polyclonal antibodies are 
produced from repeated immunization of various species (e.g., mouse, goat, donkey, sheep, 
chicken and so on). They are a heterogenous mixture of antibodies against various isoforms of 
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the target proteins. Compared to monoclonal antibodies, they have higher affinity, but lower 
specificity. Polyclonal antibodies in general suffer from a lack of reproducibility due to batch-
to-batch inconsistency. Monoclonal antibodies derive mainly from rabbit and mouse. 
Compared to polyclonal antibodies, they exhibit higher specificity and homogenous affinity 
to antigen. Hence, cross reactivity with other antigens will be significantly reduced with 
monoclonal antibodies. However, in the case of close similarity in shape or in amino acid 
sequence of the targeted peptides, cross reactivity may occur [158]. In addition, monoclonal 
antibodies are relatively complicated and expensive to produce and vulnerable to epitope-loss 
due to unmasking or fixation treatments. This issue can be offset by pooling two or more 
monoclonal antibodies to the same antigen [159]. Overall, monoclonal antibodies have proved 
effective reagents in terms of specificity for routine diagnostic practice. 
 
Successful IHC assays are highly dependent on the selection of proper antibodies. An 
important principle for validation is antibody reproducibility. Almost all the primary 
antibodies used in this thesis are commercially available and FDA approved for in vitro 
diagnostic (IVD) assays. The only exceptions were the antibodies for CD66b and CD204. 
However, these were extensively cited in the literature. Table 3 is an overview of the applied 
primary antibodies. Even though IVD antibodies are highly reproducible and require minimal 
optimization in single IHC, there are some issues that needs to be considered in the mIHC 
setting such as: The antibodies should be 1) oriented in proper disposition within staining 
cycles, 2) paired with fitting chromogens with regards to either cellular compartmentalization 
or disposition, and 3) validated in the target tissue and in controls. 
 
Table	3:	List	of	primary	antibodies	
Antibody	 supplier	 Cat.no	 Clone	 Host	 Reagent	
status	
CD66b	 BD.Bioscience	 #	555723	 G10F5	 mouse	 RUO	
CD34	 Roche	 #790-2927	 QBEnd/10	 mouse	 CE-IVD	
Pan-keratin	 Roche	 #	760-2135	 AE1/AE3/PCK26	 mouse	 CE-IVD	
CD68	 Roche	 #790-2931	 KP-1	 mouse	 CE-IVD	
CD163	 Roche	 #	760-4437	 MRQ-26	 mouse	 CE-IVD	
HLA-DR	 Dako	 M074601-2	 TAL.1B5	 mouse	 CE-IVD	
CD204	 TransGenic	 #KT022	 SRA-E5	 mouse	 RUO	




3.5.4 Staining controls 
 
Multiple immunolabeling requires stringent controls and careful combination of enzymes and 
chromogens to achieve the best color discrimination (contrast) of the IHC reaction. Although 
the primary antibodies applied in this thesis have been extensively validated by vendors, it is 
always recommended to control the specificity and sensitivity of antibodies using both 
positive and negative controls [159].  
 
Tissue controls: In each staining run, a TMA slide containing multiple samples of normal and 
tumor tissue was included to verify the quality of staining across different tissue types. The 
multi-TMA control involved selections of normal (skin, breast, liver, pancreas, colon, tonsil, 
ventricle, kidney, prostate, lung and brain) and malignant tissues (melanoma, basal cell 
carcinoma, ductal/lobular carcinoma, hepatocellular carcinoma, colon/prostate ADC, 
sarcoma, lung ADC/SCC, glioma and glioblastoma). The TMA control is carried out the same 
way as test samples. In study I and III, the key parameters in the characterizing of our 
antibodies was whether the antibody captures its cognate cellular antigen. In study I, the 
neutrophils were effortlessly identified in tissue controls, due to their multilobulated nucleus 
characteristic. In contrast, macrophages exhibit complex morphology and have the additional 
drawback of false positive staining with many antibodies. For this reason, macrophages were 
labelled with more than one marker. The documentation of the exact cellular and subcellular 
locations for immunoreactivity of macrophage markers is listed in paper III, Table S3.  
 
Processing controls: Assessing the expression of vimentin (positive in endothelial and 
mesenchymal cells) is recommended as a measure of internal quality control in 
immunoreactivity [160]. The level of its expression may verify the quality of antigen 
preservation and the uniformity of tissue fixation in FFPE samples. The vimentin expression 
in stroma was evaluated in our initial cohort (with 335 patients). In addition, both for the 
purpose of validation and categorization (stroma vs tumor), pan-keratin was integrated in the 
mIHC protocol (paper I and III). Homogenous epithelial staining intensity was observed for 
pan-CK in almost all TMA sides.   
 
Negative controls: Omitting the primary antibody is a conventional negative control for the 
secondary antibody and detection kits. The alternative negative control is utilizing isotype 
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match control, which is same class and type of immunoglobulins from which the primary 
antibody is derived. With this tool it is possible to distinguish if there is unspecific binding to 
tissue depending on the Fc domain of the immunoglobulin, and not on the idiotype [161]. In 
each mIHC sequence, both methods (isotype and no-antibody) were tested to check for cross-
reactivity between the secondary antibody and the detection reagents as well as with other 
sequences. 
 
3.6 Histological assessment 
3.6.1 H&E slides 
 
In study II, TILs were defined as lymphocyte and/or plasma cell infiltration and assessed in 
whole tissue H&E slides by manual light microscopy. A team of experienced pulmonary 
pathologist designed a scoring scheme based on the recommendations for TIL scoring in 
breast cancer by Salgado et al. [92]. TILs were scored as the percentage of tumor stroma 
containing mononuclear immune cells using a four-tiered ordinal scale: 0=0-5 %, 1=6-25%, 
2=26-50% and 3>50%. The scores from multiple areas (at least five high power fields) were 
averaged for the final count. The definition of the tumor-associated stromal region was 
crucial. For clarification, Figure 6 exemplifies the definition of tumor-associated stroma in 
H&E slides. Interestingly, different stromal configurations were observed depending on the 
level of immune infiltration (low to high). In tissues with low TIL levels, stroma appeared 
fibroblastic without the presence of TLSs, while tissues with high TIL levels were rich in the 
number of TLSs. In breast cancer, this latter group of patients (>50% of stroma occupied with 





Figure 6: The stromal areas included for TILs assessment. 
A) Tumor border were marked with blue color and the stromal areas (green rectangular) within this region were 
considered for scoring (at least 5 HPF). The normal area outside the tumor and the necrotic areas (red marked) 
were excluded (magnification x5); B) x20 magnification of stroma area; C) x20 magnification of necrotic area 
within the tumor cores. 
 
In order to maximize the reproducibility of the scoring model and minimize the inter-observer 
variations, the following parameters were not included in the scoring scheme: granulocytes of 
any type, TLSs, necrotic areas, tumor borders (invasive margins) and normal alveolar areas. 
Table 4 is a side-by-side comparison between the original scoring criteria for TILs in breast 
cancer and the adjustments made for scoring TILs in NSCLC, showing the degree of 





Table 4: Comparing TILs assessment guideline in breast cancer and the criteria executed in study II. 
Original guideline Adopted criteria in study II 
TILs should be reported for the stromal 
compartment and in percentage (=% stromal 
TILs). 
 
Accordingly, TILs were scored in stromal 
compartment. 
TILs should be evaluated within the borders of 
the invasive tumor. 
 
Inter-tumoral stroma included in our assessment 
(see details in Figure 6). 
Exclude TILs outside of the tumor border and 
around DCIS and normal lobules. 
 
Normal alveolar area was excluded. 
Exclude TILs in tumor zones with crush artifacts, 
necrosis, regressive hyalinization as well as in the 
previous core biopsy site. 
 
Necrotic area and regions having crush artifact 
were excluded. 
All mononuclear cells, including lymphocytes and 
plasma cells, should be scored, but PMN 
leukocytes are excluded. 
 
Lymphocytes and plasma cells considered as TILs 
and tumor-associated granulocytes were 
excluded. 
One section (4–5 µm, magnification ×200–400) 
per patient is currently considered to be 
sufficient. 
 
1-2 section per patient were used for analysis 
with x200 magnification, and if needed x400. 
A full assessment of average TILs in the tumor 
area by the pathologist should be used. Do not 
focus on hotspots. 
 
Average score of at least five area were used as 
final score. 
Scoring scale according to original methodology 
firstly described by Denkert et al. [91] 
Continuous per 10%. 
 
A four-tiered scale designed by four experienced 
lung cancer pathologists: 
0=0-5 %, 1=6-25%, 2=26-50% and 3>50%. 
No formal recommendation for a clinically 
relevant TIL threshold(s) was given. LPBC can be 
used as a descriptive term for tumors that 
contain more lymphocytes than tumor cells. 
However, the thresholds vary between 50% and 
60% stromal lymphocytes. 
 
Multi-level cutoff was used. 
Additional parameters, including TLS in the 
peritumoral region, TILs at the invasive edge or 
intratumoral TILs can still be included for 
research purposes to further determine and/or 
confirm their potential clinical relevance. 
 
TLS, intraepithelial and invasive margin TILs were 
not included in our assessment. 
Abbreviations: TILs, tumor-infiltrated lymphocytes; LPBC, lymphocyte-predominant breast cancer; 
TLS, tertiary lymphoid structures. 




3.6.2 IHC analysis 
 
In study I and III, a semiquantitative scoring model was applied for visual assessment of the 
neutrophil and macrophage infiltration in different compartments. In primary tumors, 
intratumoral and stromal areas were scored separately, while in the LN+ cohort only 
intratumoral areas were scored. In LN+, the reason for exclusion of stroma was: 1) high 
abundance of immune cells, 2) difficulty to differentiate between normal- and tumor-
associated stroma regions. 
  
In stroma, the overall percentage of positive neutrophils or macrophages among nucleated 
cells were scored as follows: 0 (0–5%), 1 (6–25%), 2 (26–50%) and 3 (>50%). In the 
intratumoral compartments (paper I), due to the lower presence of target cells in tumor 
compared to stroma, the following four-tiered scale was applied: 0 ≤ 1, 1 = 1-5, 2 = 6-15, 3 
>15. Notably, macrophages were less prone to infiltrate into the tumor area. Hence a three-
tiered scale was applied: 0 (no cells), 1 (1–5), 2 (³6). LN+ cohorts were scored similar to the 
intratumoral scoring models.     
  
Even though manual scoring is practical, it is based on subjective visual perception. The 
semi-quantitative nature and low reproducibility of manual scoring is often criticized. To 
minimize the subjectivity of our assessments, the following available options were adhered to: 
excluding areas with high risk of error (false positive/negative count), and analyzing the inter-
observer variability. 
 
Excluded areas: For both neutrophils and macrophages, necrotic and pre-necrotic areas 
presented highly infiltrated zones and were ignored to avoid false positive counts. Moreover, 
areas where neutrophils resided together with their released granules (due to neutrophil 
autolysis), and areas with neutrophil aggregates (Figure 7) were ignored.  
 
In addition, it is known that the systemic inflammatory response caused by cancer is 
associated with alterations in circulating leukocytes, specifically with signs of neutrophilia 
and lymphocytopenia in advanced NSCLC [162,163]. With this understanding and in order to 
avoid the potential bias of circulating/intravascular neutrophils, neutrophils clearly located 





Figure 7: Excluded areas for scoring in study I. 
Representative CD66b (brown)+CD34 (purple)+pan-CK (yellow) mIHC stained TMA slides scanned by a pathology 
digital imaging system (Pannoramic P250 Flash III whole-slide scanner; 3DHistech, Hungary). Red arrows from 
the schematic model (adopted from paper I with modification) indicating the areas excluded in scoring. 
  
Inter-observer variability: Two observers, blinded to patient clinical data, scored all stained 
slides. In general, there was a strong agreement between scorers with regard to inter-observer 
correlation coefficient. Interestingly, high interobserver kappa values were observed in study 
I and III wherein mIHC was implemented for the purpose of accurate differentiation of 
positive cells. This may indicate that the technical approaches chosen for these studies, led to 
reduced interobserver variation. In the manual scoring setting for various markers, it is 
common to carry out reassessments if there is a two-score disagreement or more between the 
observers. In such a case the slides go for reassessment to reach a consensus. In study I and 
III, there was almost no disagreement between observers further highlighting the advantage 




Recently, digital image analysis has started to compensate for the variability of human 
perception. Current imaging technologies are capable of measuring characteristics that are 
extensively beyond the reach of human visual subjective observations. In addition, the 
information that could be uncovered through detection of multiple biomarkers by mIHC, is 
critically important in developing a fully quantitative model to evaluate IHC. 
 
3.7 Cutoff identification 
 
Biomarkers are direct or indirect measures of biological processes. Even though biological 
processes are inherently continuous, it is often necessary to use a cut-off value to apply a 
biomarker in prognostication or treatment-decision-making. The cut-off value will typically 
stratify the patients into two or more groups based on a risk-profile. The alternative would be 
to use a continuous scale as this would be a true reflection of the biological process. Although 
a tempting approach, the shear complexity of using continuous scales and the number of 
patients needed to conduct meaningful trials is for the moment precluding its use. In the field 
of biomarker discovery, no standard tool (similar to Allerd or IR score) to convert a metric or 
ordinal variable into a discrete variable exist. Thus, the chosen cut-off(s) are likely to be 
error-prone.  
 
The number and values of the cut-off may be based on previous results (confirmatory 
studies), clinical or physiological data, mean or median values, tertiles, quartiles or quintiles, 
greatest separation of groups (lowest P-value) or other approaches. All these approaches have 
limitations related to risk of type I and II errors. Provided an exploratory design, it is up to the 
investigator to choose the cut-off strategy. In some of the studies included in this thesis 
(paper I and III) mean cut-offs were used. Mean cut-offs are resistant to type I errors, but 
may be prone to type II errors if the effect of the biomarker is only evident in either strong 
positive or negative cases. In addition, a mean cut-off may be easier to reproduce compared to 
for instance an optimal cutoff. In study III (for CD68), an optimal cut-off strategy was 
applied. Although, caution is advised when using optimal cut-offs [164], this strategy is 
commonly used in explorative studies [165,166]. Optimal cut-off strategies increase the 
chance of type I errors and reduces the chance of type II errors. Subgroup analyses, for which 
many explorative studies are underpowered, should be considered with caution as the chance 
of type I errors increases as number of patients in each group dwindles. In addition, 
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reproducibility might prove to be an issue, especially when optimal cut-offs are applied to 
semi-quantitative scores.  
 
Of the studies included in this thesis, study II may have the most robust form of cut-off as the 
original scores is used without further modification. This scoring model seems to be easily 
reproducible and reliable for potential translation into the clinic  
 
3.8 Statistical analysis 
 
All statistical analyses were performed using two programs: IBM SPSS (v23-25) and Rstudio 
(v3.2.2; packages: survival, gridExtra, car, Hmisc, irr and ggplot2). The association of TAN, 
TIL and TAM levels and different clinicopathological parameters was evaluated using chi 
square and Fisher’s exact tests. Interobserver reliability was calculated using a two-way 
random-effects model with an absolute agreement definition and Cohen's kappa coefficient 
with equal weighting. A non-parametric test (Mann–Whitney U) was used since the patients 
were not normally distributed across pathological stages (paper III). Spearman correlation 
coefficient was used to examine the associations between protein/protein expressions and 
when needed Bonferroni correction was applied. Kaplan-Meier estimates were plotted for 
DSS, OS and DFS. Log rank test was used to test the statistical significance of the difference 
between low/high and stepwise increased groups. A multivariable cox model, with estimated 
hazard ratios (HR) and 95% confidence interval (CI), was used to model associations between 
survival and known prognostic variables (age, pathological stage, ECOG score, gender, 
vascular invasion and differentiation). Stepwise backward conditional selection using 0.10 
and 0.05 as entry-and exit-points was used to select variables for the final models. Two-tailed 




4 Main results 
4.1 Paper I 
 
The clinical impact of tissue-based neutrophils is still unclear in NSCLC. Using mIHC, 
CD66b+ TANs were evaluated in primary tumors and paired metastatic lymph nodes. The 
positive cells were manually scored in the tumor and stroma compartments, based on criteria 
described in Section 3.6.2. In short, pre-/necrotic areas and intravascular neutrophils were 
ignored. CD66b showed membranous and cytoplasmic localization on neutrophils. 
  
Correlation: In the overall cohort, intratumoral TANs were positively associated with 
increasing tumor stage (P = 0.011) and pathological stage IIB (P = 0.002). In SCC, TANs 
were negatively associated with nodal stage (P = 0.032). In the overall cohort and SCC 
subgroup, stromal TANs were associated with weight loss (P = 0.044, P = 0.031; 
respectively). No associations between clinicopathological variables and TANs were detected 
in the ADC or LN+ groups. Correlation analyses were performed between TANs and 104 
tumor molecular markers previously evaluated in this cohort. Concisely, there was a 
significant correlation between TANs and innate immune-related markers including: CD68, 
CSF1R and MCSF. 
 
Survival analysis: For stromal TANs, no significant impact on patient outcome was observed 
in the overall cohort and histology subgroups. For intratumoral TANs, when stratified 
according histology, high level in the SCC subgroup was an independent positive 
prognosticator for DSS (univariate P = 0.038, multivariable P = 0.021, HR 0.59, CI 0.38-
0.92). In contrast, we found a significantly shorter DSS for primary tumors with high level of 
TANs in the ADC group (univariate P = 0.032; multivariable P = 0.020, HR 1.7, CI 1.1-2.65). 
Consistently, in LN+ ADC histology, high level of intratumoral TANs was associated with 
poor prognosis (univariate P = 0.003; multivariable P = 0.004, HR 2.87, CI 1.39-5.91). In 








4.2 Paper II 
 
Normally, TILs are ignored during the routine diagnostic process on H&E slides of resected 
tumors. However, accumulating data show that in situ TILs, even in routine H&E slides, can 
provide pivotal prognostic and predictive information. Currently, there is a guideline available 
for evaluation of TILs in H&E slide for breast cancer. Hence, we aimed to validate the 
compatibility of this guideline´s criteria for use on NSCLC whole tissue H&E slides. The 
following areas and cells were excluded from assessment: Intraepithelial TILs, tumor-
associated granulocytes, TLSs, invasive margins, normal and necrotic regions.  
 
Correlation: In the overall cohort, higher level of TILs was statistically associated with a 
favorable ECOG performance status. 
 
Survival analysis:  In the overall cohort, high TIL levels was associated with better outcome 
for DSS, DFS and OS (P=0.008, P=0.006 and P=0.036 respectively). In the SCC subgroup, 
high TIL levels was a positive prognostic factor for DSS (P=0.047) and a positive trend was 
observed for OS and DFS (P=0.058, P=0.054). In the ADC subgroup, high TIL levels 
conveyed no survival benefits for any clinical endpoints. Multivariable models adjusted for 
known prognostic factors including pathological stage, histological differentiation, vascular 
invasion, gender and age were conducted. Elevated TIL levels were independent positive 
predictors of OS (P=0.006, HR 0.51, CI 0.32-0.82,), DSS (P<0.001, HR 0.3, CI 0.15-0.6) and 
DFS (P<0.001, HR 0.34, CI 0.19-0.64). When patients were stratified according to TNM 
stage, TIL levels was a nearly significant positive prognostic indicator in stage II (DSS, 







4.3 Paper III 
 
The significance of TAMs in NSCLC has been the subject of conflicting reports. The present 
study was designed to set up a reliable IHC-based method in order to phenotype, and to 
evaluate the clinical significance of TAMs in NSCLC. As TAMs are thought to differentiate 
mainly into two anti-tumoral M1 and pro-tumoral M2 subsets, the study aimed to phenotype 
TAMs using mIHC with the following marker combinations: HLA-DR/CD68 (M1), 
CD163/CD68(M2), CD204/CD68(M2) and CD68/CK (pan-TAM). 
 
Correlation: Stromal M1 was associated with T-stage and ECOG status and CD204+M2 was 
associated with patient age. In the intratumoral compartment (both for primary tumors and in 
the LN+ cohort), M1 was associated to ECOG status. Correlation analysis was performed 
between TAMs and innate/adaptive immune-associated markers, previously evaluated in this 
cohort. In both stromal and intratumoral compartments, moderate to strong correlations were 
observed between TAMs (both M1 and M2) and CD3, CD8, CD4 and CD45RO positive 
immune cells. When TAMs distribution was assessed across TNM stages, levels of stromal 
CD163+M2, CD204+M2, and CD68 infiltration did not differ significantly, but notably 
declined for M1 from pathological stage I to III. 
 
Survival analysis: In multivariable models, stromal M1 (HR 0.73; CI 0.5-0.97; P=0.03), 
CD204+M2 (HR 0.7; CI 0.5-0.94; P=0.02) and CD68 (HR 0.69; CI 0.5-0.94; P=0.02) and 
intratumoral M1 (HR 0.7; CI 0.5-0.99; P=0.04), CD204+M2 (HR 0.6; CI 0.4-0.8; P=0.004) 
and CD68 (HR 0.73; CI 0.5-0.99; P=0.04) were independent favorable prognostic indicators 
of increased DSS. In the LN+ cohort, high intratumoral M1 level was an independent 
favorable indicator of DSS (HR 0.38; CI 0.2-0.7; P=0.001). 
When stratified according to histology, high levels of stromal CD163+M2 (P <0.001) and 
CD204+M2 (P= 0.005) and both stromal and intratumoral M1 (P <0.001, P=0.016) subsets, 
were associated with increased DSS in the SCC subgroup, while high levels of stromal CD68 






5.1 Tumor-associated neutrophils  
 
As seen in paper I, our results show that intratumoral TANs have diverging prognostic 
impact in the ADC and SCC subgroups of NSCLC. This may explain why no prognostic 
impact was observed in the overall cohort. 
 
A recent meta-analysis showed that high in situ neutrophil infiltration is associated with 
unfavorable outcome in solid tumors [167], however the role of neutrophils in NSCLC is still 
unclear. Overall, the presence of neutrophils are associated with unfavorable outcome in 
bronchioloalveolar, esophagus, renal cell, and head & neck cancers [106,109–111], but with a 
favorable outcome in colorectal and gastric malignancies [112,113]. In a previous study in 
NSCLC, the ratio of CD66b+ TAN/CD8+ T-cells was associated with increased risk of 
progression and shorter OS [115], while another study found no association between 
neutrophils and clinical outcome [168]. 
 
The data on the biological activity of TANs are majorly derived from experimental model 
studies, rather than studies in human. The findings from animal models underscore the 
influence of the TGF-β pathways on TAN recruitment and activation of CD8+ TILs [169]. 
For instance, in a mouse model study, they found that TGF- β signaling is pivotal to 
differentiate PMN subset of MSDCs, and to induce a distinct N2 TAN phenotype with tumor-
promoting properties. Also, abrogation of TGF- β signaling differentiated TANs from a N2 to 
N1 phenotype with anti-tumoral effect. Further, N1 subset depletion reduced CD8+ T-cells 
function and promoted tumor growth [101]. In fact, N1 TAN mediated CD8+ T cell activation, 
is postulated as the main mechanism for tumor-inhibition responses exerted by these cells. 
Despite the many differences between tumor-bearing mice and humans, the same may apply 
to tumors in humans. Macrophages and neutrophils derive from the same progenitor, thus the 
complexity of macrophage differentiation in humans is also likely for neutrophils [170]. In 
this study, we observed strong associations between TANs and CD68+ TAMs, and expression 
of CSF1R and MCSF. 
 
Human TANs may distinctively influence tumor immunity depending on tumor stage and 
histology. In early stage NSCLC, TANs are not mainly immunosuppressive; instead they 
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stimulate T cell-mediated immune reaction by producing co-stimulatory molecules that 
increase the proliferation of CD4+ and CD8+ TILs [171,172]. The mechanisms by which 
human TANs influence immunity is poorly understood. Moreover, it is unclear whether in 
vitro data from murine studies, supporting the notion of N1 /N2 TANs, can be applied to 
humans. TANs are influenced by a wide range of signaling molecules that differ between and 
within different stages of the same histological subtype. Thus, the prognostic significance of 
TANs may vary, not only according to histological subtype, but also due other tumor intrinsic 
properties such as oxygenation, nutrient supply, etc. Adding complexity, the predominant 
NSCLC histological phenotypes (SCC vs ADC) are often regarded as different entities, with 
distinct genomic and morphological profiles, growth patterns and sensitivity to treatment 
[173]. 
 
5.2 Tumor-infiltrating lymphocytes  
 
In this study, the guideline for assessing TILs using standard H&E slides in breast cancer 
were validated for use in NSCLC. The results show that increasing levels of stromal TILs is a 
strong independent prognostic factor for DSS, OS and DFS in NSCLC patients. While others 
have explored overall TILs on H&E in lung cancer before, this is the first large study to 
incorporate well-defined scoring methods for reliable evaluation of TILs in NSCLC patients 
using routine H&E slides. 
 
The prognostic significance of TILs in primary NSCLC has been investigated in numerous 
studies [174]. However, only a few of these studies utilized routine H&E staining (rather than 
IHC) to assess lymphocyte infiltration [81,94–98]. High TIL density was associated with 
increased survival in three of the studies on pathological stage I [96,97] or III [98]. A large 
Italian-cohort study (including 1290 patients) found survival benefit of high TILs infiltration 
in the SCC histology (549 patients), while no survival-association observed in their whole 
cohort [95]. In a large TMA-based study, high level of CD8+ TILs was correlated with 
improved survival, while TILs evaluated with H&E did not show a significant difference [81]. 
In the current study, we found an association between stromal TILs and all clinical endpoints 
in the whole cohort, consistent with the findings of another recent large NSCLC study by 
Brambilla and coworkers [94]. In addition, TILs in the SCC patient subgroup, were found to 




There is strong support for the prognostic significance of TIL in NSCLC, but there is no 
standardized method for assessing TILs in whole tissue H&E slides. To design a consistent 
approach to assess TILs in this setting (see Section 3.6.1), three histological components were 
excluded:  
 
1. Intratumoral TILs. Intratumoral TILs have prognostic and predictive associations in breast 
cancer patients [91], but in the setting of NSCLC it was difficult to differentiate between 
tissue lymphocytes and apoptotic tumor epithelial cells. For this reason, intraepithelial TILs 
were considered unscorable. A recent study observed low interobserver agreement among 
scorers, and poor reproducibility for quantifying TILs in the intraepithelial compartments 
[175].  
 
2. TILs within the invasive margins. TILs within the invasive margins in CRC have an 
important prognostic role [176,177]. One study on liver metastases of CRC found that a high 
CD8+ T-cell density in invasive margins was associated with improved prognosis and 
response to chemotherapy; the investigators defined the invasive margin as an area of 500 µm 
on each side of the edges between tumor epithelium cells and normal tissue [177]. However, 
due to the highly unstable growth patterns of some NSCLCs, the invasive margin was not 
considered in order to increase the reproducibility of the results. 
 
3. Tertiary lymphoid structure (TLS): TLSs may have a critical antitumoral role by inducing 
systemic and local T-cell immune responses and are observed in many solid tumors, including 
lung cancer [178]. In NSCLC, the density of TLS-localized mature dendritic cells has been 
associated with increased survival [83]. TLS have similar structures to lymph nodes, 
comprising T-cell-DC clusters, follicular B cells, and high endothelial venules. In the original 
guideline, TLS were recommended to be exclude or evaluated as a separate research 
parameter (Table 4 in Section 3.6.1). 
 
Subgroup analyses according to pathological stages revealed high density of TILs to be near-
significant prognostic factor for patients with stage II and III. A trend for this relationship was 
also noted in stage I tumors. Two previous NSCLC studies found that high TIL density is also 
associated with improved overall survival in stage I disease [95,96]. We found no statistically 
significant prognostic impact in stage I patients, which is consistent with previous reports 
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on other early stage cancers involving esophageal, colorectal and breast [179–181]. TIL 
levels may therefore have a stronger prognostic role in NSCLC with more aggressive 
phenotypes. These results should be interpreted with caution. Further studies powered for 
subgroup analyses would be valuable, especially in patients with stage I NSCLC.  
 
Although rational, the present study is the first to demonstrate that a stepwise increase of TIL 
levels in tumor stroma leads to a stepwise increase in patient prognosis. Feng et al. [98] did 
not detect any prognostic potential of TILs using a four-step method. The detailed scoring 
system proposed in this study should be easy to use and will likely reduce inter-observer 
variation and enhance detection of the prognostic potential of TILs in NSCLC. Even though 
the assessment of TILs would be simple, inexpensive, and easy to introduce into routine 
practice, it is still a semi-quantitative measurement and may be further refined using digital 
cell-counting systems. 
 
5.3 Tumor-associated macrophages  
 
Many studies have evaluated the prognostic potential of TAMs in NSCLC, but the 
significance is debatable and would also benefit from further investigation. To the best of our 
knowledge, this is the first large-scale study to investigate the prognostic significance of in 
situ TAMs in NSCLC. Independent positive associations between high levels of HLA-
DR+M1, CD204+M2 and pan-CD68+ TAMs and DSS, were found in both tumor stroma and 
in the intratumoral compartments. 
 
Traditionally analyses of TAMs have been based on CD68 expression alone [182]. In a 
previous study of 335 patients from our group, using single-color IHC a positive trend 
between high CD68+TAM levels in both stromal and intratumoral compartments was noted 
[183]. The current study used a larger number of patients and co-stained samples with pan-
CK. In multivariable analyses, we found a statistically significant relation between high levels 
of CD68+ TAMs and a favorable prognosis. Table S7 (paper III) summarizes previous 
studies on the prognostic impact of TAMs in NSCLC. Two of these studies, by Kim [184] 
and Eerola et al. [185] also showed improved outcomes associated with high intratumoral 
densities of CD68+TAMs. However, some studies found negative [186–188], none [189–191] 
or diverging [192,193] associations. This inconsistency may relate to methodologic difference 
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and CD68 antibody specificity. As interpretation of IHC stains varies considerably, the 
reproducibility of CD68 scoring is also variable. Some of this variability may relate to 
expression of the marker in tumor cells and other immune cell infiltrates [194]. We found 
CD68 positivity in the tumor cells of 23% of our patient sample. 
 
Non-specific staining may overestimate TAM density, but the use of pan-CK to differentiate 
between epithelial and non-epithelial cells improves accuracy when detecting intratumoral 
CD68+TAMs. Some studies use digital analysis to quantify TAMs [114,195]. For the 
detection of TAMs, digital analyses may be biased more compared to using visual 
microscopy due to  the wide variation in the size of macrophages (5–30 µm) in the lung tissue 
[196]. In the future, detection of TAMs using digital pathology will likely rely on a 
combination of artificial intelligence or computer vision, that depend on huge annotated 
datasets of TAM morphology and antibody panels designed especially for this purpose. 
 
Currently there is no consensus on the most accurate methods for identifying and 
differentiating tissue-based macrophage subsets in solid tumors. Recent studies use multiple 
antibodies to identify macrophages and to characterize TAM subsets [197]. The most 
common markers for M2 identification when co-staining with CD68, or using a single IHC 
assay, are CD163, CD204 and CD206 [198]. For identifying the M1 subset, the best choice of 
antibodies is undecided. Some studies used HLA-DR [195,199–201], but this is expressed on 
the membranes of antigen-presenting cells, including macrophages, monocytes, dendritic 
cells, B cells, activated T cells [202] and tumor cells [203]. In NSCLC, only two studies used 
mIHC to analyze TAM subsets. The others used single-IHC against M2 antigens (e.g., CD204 
or CD163) (see Table S7 in Paper III). Intratumoral subpopulations, including M1-like and 
M2-like TAMs, were found to predict superior outcomes in NSCLC patients [199]. We also 
found a survival benefit in relation to high M1 or M2 phenotype levels in both tumor islets 
and stroma. In one study, only the intratumoral M1 subset (not M2) was found to have 
independent prognostic significance [195]. However, investigators in both of these studies 
[195,199] were unable to identify a statistically significant association between stromal TAM 
subsets and survival. 
 
There is a higher proportion of immune cells in tumor stroma than in intratumoral tissue, 
where some subsets of immune cells are positive for the markers studied here, together with 
TAMs. Additionally, IHC-based analysis of TAM subsets in stroma requires a reliable 
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method to account for co-localized macrophage markers. For this reason, we carried out 
several experiments to characterize the macrophage subsets. Due to the challenges of mIHC, 
(discussed in Section 3.5.2), we tested different chromogens and enzymatic reactions to 
determine the most appropriate color combination for visual assessment of co-localized areas. 
Using translucent chromogens enabled us to reliably label co-localized antigens of interest on 
TAMs. We found that the commonly used DAB/red dual-chromogen set was unreliable 
because of the dominant brown color. 
 
We had two novel findings in the study. First, the level of intratumoral M1 subset in 
metastatic lymph nodes was found to be an independent positive predictor of prognosis. This 
is in line with its prognostic role in primary tumors. There was no significant correlation 
between TAM subsets in lymph nodes and those in primary tumor tissue, possibly because of 
the heterogeneity of macrophages in the tissues [204]. Second, stromal infiltration of M1 
significantly dropped from stage I to stage III. This is in support of the finding that 
macrophage phenotypes change from proinflammatory to immunosuppressive states during 
the disease course [205]. It also supports the findings of an animal study of advanced stage 
hepatocellular carcinoma in which a high M1-like phenotype found in the early stage changed 
to a low M1-like phenotype [206]. Some of the complexity of macrophage expression relates 
to this temporal plasticity during tumor development. 
 
From a biological perspective, M1 and M2 macrophage subsets are expected to associate 
inversely with tumor-inhibiting or tumor-promoting effects, respectively. However, studies on 
NSCLC, CRC and gastric carcinomas (including the current study) observed that infiltration 
of both M1 and M2 subtypes were positively associated with clinical outcome [199,207,208]. 
Different inferences can be made regarding the survival benefits of M2 TAM infiltration. 
Further research might reveal mutual interactions between M1 and M2 TAMs in NSCLC 
[199]. In CRC, the M1 antitumoral activity may dominate over the M2 protumoral activity 
since the two subtypes co-exist, thus leading to improved outcomes [207]. Further, in the 
unique intestinal environment that comprises various microorganisms, macrophages may 
require this functional alteration to maintain gut-tissue homeostasis [207]. The prognostic 
influence of TAMs may relate to lymphocytic infiltration; this is based on observations of 
high levels of both TILs and CD163+M2 in gastric cancer [208]. In our study, the moderate to 
strong correlation between M1 and M2 with lymphocytic infiltration of CD3, CD8 and CD4 
cells implies that both phenotypes are involved in effective recruitment of lymphocytes, 
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operating with T-helper and cytotoxic cells to induce an antitumoral response [124]. 
Interestingly, a recent study found a close relation between the quantity of CD206+ M2-like 
TAMs and “bystander” CD8+ TILs in lung tumor stroma of TAM-depleted mice [209]. They 
also found that TAMs have prolonged interactions with CD8+ TILs in the stroma, limiting 
their entry into cancer islets and thus interrupting their antitumoral activity [209]. 
 
Taken together, the distribution of macrophage phenotypes clearly differs between different 
tissues and within specific tissues, in terms of polarization, disease stage and environmental 
signals. This degree of macrophage plasticity limits understanding of the role of M1 and M2 
subtypes in the distinct protumoral and antitumoral activities of tumors. The existing 
nomenclature based on macrophage function probably has little relevance in the complex 





6 Concluding remarks and outlook 
 
Numerous studies have detected prognostic and predictive markers, both for cancer in general 
and for NSCLC in particular. However, only a few have entered clinical studies and even 
fewer to clinical practice. This is in stark contrast to the need of tools to select, or to spare, 
patients for an ever-increasing arsenal of treatment options. Immune cell infiltration to the 
malignant environment is a typical feature of many solid neoplasms. Over the past decade, an 
extensive body of evidence have demonstrated a fundamental interaction between 
inflammatory and cancer cells. In NSCLC, our group found that patients with high levels of 
CD8+T-lymphocytes in the malignant environment, exhibited better disease-specific and 
overall survival when compared to patients with low levels [79]. This work was followed by a 
recommendation to include IHC-based immune profiling in routine practice as NSCLC TNM-
Immune cells score classifier [89]. The studies in this thesis were conducted to further the 
understanding of the immune contexture, and to search for novel immune markers in NSCLC. 
Neutrophils, lymphocytes and monocytes are the most abundant subsets of leukocytes in 
blood and tumor tissues. While the positive prognostic impact of adaptive immune cells are 
widely investigated in most cancers, the prognostic impact of innate immune cells are 
suffering from discrepant reports in different cancers, including NSCLC. In paper I, we 
identified intratumoral neutrophils to be both an independent positive and negative predictor 
of prognosis in the SCC and ADC subgroup of NSCLC patients, respectively. However, we 
were not able to provide a definite answer why the prognostic influence diverged in these two 
main subgroups. When tested in pathological subgroups, we proposed the level of CD66b+ 
neutrophils as an appropriate candidate marker for a NSCLC-ADC TNM-I, along with other 
proposed markers such as CD8+ and CD45RO+ T-lymphocytes. However, these preliminary 
results require validation in larger cohort of NSCLC-ADC patients.  
In paper III, a technical strategy for the assessment of colocalized markers in chromogenic 
IHC-based assays was described. Moreover, we demonstrated that the high infiltration of 
macrophages into the primary tumors of NSCLC patients (HLA-DR+M1, CD204+M2 and 
pan-CD68 macrophages) are independent determinants of better clinical outcome. In 
metastatic lymph nodes, high level of HLA-DR+M1 phenotype was an independent favorable 
prognosticator. We also observed there is a phenotypic shift from high to low levels of HLA-
DR+M1 macrophages during the development of disease across pathological stage I to III. 
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These results are in contrast to preclinical studies that supports the theory of distinct M1 anti-
tumor and M2 pro-tumor macrophages. While the reason behind the positive survival-
association of both M1 and M2 macrophages in NSCLC remains elusive, the significant 
correlation between these two phenotypes and adaptive immune cells clearly warrants further 
attention. 
In paper II, we found that stromal TIL levels, evaluated in routine H&E slides, are predictors 
of favorable prognosis in NSCLC patients. This finding confirms a previous study by 
Brambilla et al. [94]. However, in contrast to Brambilla, we found that a four-tiered score 
provided prognostic information in a step-wise manner likely reflect the underlying biology. 
The study was conducted in accordance to the original guideline for TILs assessment in breast 
cancer with some minor adjustments for use in NSCLC. We concluded that H&E TILs is a 
promising candidate for a NSCLC TNM-I. H&E TILs are especially attractive because they 
are evaluated in the same H&E slides already used for histopathological reporting and thus is 
easily integrated in current clinical practice.  
Multiple hurdles must be crossed prior to the execution of a novel prognostic or predictive 
marker in a clinical setting. In order to ensure marker performance, independent prospective 
validations, in different patient cohorts, are needed. Notably, our research team is conducting 
a prospective multi-cohort Scandinavian study (NCT03299478) in order to validate the 
prognostic and predictive benefit of a NSCLC TNM-I in resected samples. However, the 
majority of lung cancer patients are diagnosed in advanced stages. For most of these patients 
surgical resection is not an option and is likely to worsen an already bleak prognosis. Future 
research on the immune infiltration in lung cancer should emphasize its use on bioptic 
materials. In a clinical setting, successful assessment of immune status in biopsies may help 
select patients for immunotherapy, and could be applicable both for patients in an advanced 
and in a neoadjuvant setting. 
In summary, this thesis provides a comprehensive evaluation of the major innate and adaptive 
immune cell populations (neutrophils, lymphocytes and macrophages) and their association 
with clinical outcome in NSCLC. The novel data on the prognostic value and distribution of 
these markers, will hopefully contribute to an enhanced understanding and aid in the 
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189Tumor-infiltrating lymphocytes (TILs) in NSCLC1. IntroductionThe characteristics of the tumor microenvironment
(TME), in particular immune cells, has been a topic of con-
siderable interest in non–small cell lung cancer (NSCLC).
Different immune profiles have been proposed as prognos-
tic and predictive factors for NSCLC patients [1,2]. With
the advent of immunotherapy, assessment of the tumor im-
mune-contexture has become an even more important clinical
consideration [3].
Tumor-infiltrating lymphocytes (TILs) constitute the
predominant immune cell populations in the TME. TILs
belong to both the adaptive and innate arms of the immune
system. In NSCLC, commonly detected TIL subsets asso-
ciated with a positive clinical outcome, and previously re-
ported by our group and others, are CD3+, CD4+, CD8+,
CD20+, CD45RO+ [4-6]. Intriguingly, the presence of TILs
expressing immune-checkpoint regulators PD-1, PD-L1,
CTLA-4 and LAG-3 were also associated with improved sur-
vival [7-9].
The TNM classification system divides solid tumors
into strictly localized or more advanced disease (stages
I-IV). Although the TNM classification, combined
with histological and genetic features of the tumor,
provide valuable prognostic information, a consider-
able variation in prognosis is reported within the same
TNM stage [10]. Recently, assessments of the immune con-
texture in solid tumors has supplemented reliable prognostic
and predictive data to the TNM classification [11-13]. Our
group has previously proposed potential candidate immune
cell markers to establish a TNM immunoscore (TNM-I) for
NSCLC [5-7,14].
Most studies evaluating TILs in lung cancer have ap-
plied immunohistochemistry (IHC) to differentiate TIL
subsets and to assess their density, distribution and locali-
zation. A standardized methodology to assess TILs using
routine hematoxylin and eosin (H&E) is an attractive alter-
native to IHC as it easily integrates into the workflow of
pathology laboratories without the need of extra staining
protocols. Ease of use may prove H&E TILs as a valuable
marker when establishing an immunoscore for NSCLC pa-
tients. Only a limited number of lung cancer studies have
explored TILs in whole-tissue H&E–stained section
(WT-HE) slides [15-19]. A few of these studies used a similar
scoring scheme for the evaluation of TILs [15,19]. However,
no consensus has been reached on a standard quantification
of TILs in lung cancer WT-HE slides.
This study aims to validate a comprehensive patholog-
ical assessment of TILs, originally proposed for breast
cancer [20,21], for use on NSCLC tissues. Stromal TILs in
WT-HE slides from 537 surgically resected stage I-III patients
were assessed and confirmatory evidence of the prognostic
value of TILs for these patients is provided. Further, the poten-
tial of stromal TILs in the setting of a NSCLC TNM-I is
explored.2. Materials and methods
2.1. Patient cohort
Clinical and pathological data were obtained through a de-
tailed retrospective review of the medical records of 633 con-
secutive patients with NSCLC who had undergone radical
resection between 1990 and 2010. Out of 633 patients, 96were
excluded from the study due to: neoadjuvant radio-chemother-
apy (n = 15), other malignancy within 5 years before NSCLC
diagnosis (n = 39), inadequate tissue in paraffin-embedded for-
malin fixed blocks (n = 26) and de-colored staining or poor tis-
sue quality (n = 16). Thus, 537 patients with complete
demographic and clinicopathological data were eligible for
this study.
Most of the patients diagnosed at clinical stage II-III re-
ceived adjuvant chemotherapy. After postoperative recur-
rence, eligible patients underwent cytotoxic and targeted
therapies. A few patients received radiotherapy and/or resec-
tions due to recurrent disease.
The median follow-up of survivors was 86 months (range
34–267 months). Follow up data was last updated October 1,
2013.
The tumors have been restaged in accordance with the 8th
edition of the TNM classification [22], published by the Union
for International Cancer Control (UICC) and patient samples
have been histologically reclassified based on the 4th edition
of the 2015 World Health Organization (WHO) Classification
of Lung Tumors [23]. REMARK (Reporting Recommenda-
tions for Tumor Marker Prognostic Studies) guidelines were
followed in this study [24]. Further information regarding co-
hort has previously been published [9].
The study was approved by the Norwegian Data Protection
Authority and the Regional Committee for Medical and Health
Research Ethics (protocol ID, 2016/714).2.2. Histological evaluation
Histological analysis of TILs was performed on WT-HE
slides. TILs were assessed by two observers (S.M.D, M.R),
who were blinded to each other, clinical data and patient out-
come, using a four-tiered scale designed by four experienced
lung cancer pathologists (L.T.B, E.R, S.A.S, S.M.D). The per-
centage of tumor stroma containing mononuclear immune
cells (including lymphocytes and plasma cells) was classified
as: 0 = 0–5%, 1 = 6%–25%, 2 = 26%–50% and 3 N50%. To
obtain an estimate of mean infiltrative area, TILs were
assessed in multiple stromal regions and not only in hot spots.
In case of disagreement of 2 or more scale units, slides were
reevaluated until the observers reached a consensus. Supple-
mentary Fig. S1 is a schematic representation of which areas
were selected for assessment. The histomorphology of the dif-
ferent groups according to the scoring scheme were as follows:
(0) The stroma has completely loose or dense fibroblastic ap-
pearance with no/very rare immune cells; (1) Loose and
Fig. 1 Standard H&E–stained sections of NSCLC. A and B, Islands of necrotic squamous cells with high presence of neutrophils. C, Tertiary
lymphoid structure at the tumor border. D, Lymphoid aggregates without germinal center. E and F, Both images from a single patient specimen
represents irregular tumor border: (E) high fibrotic tumor edge, (F) inflammatory cell reaction in tumor edge, (G) adjacent normal lung, (H) TILs
and apoptotic cells (white arrows) within neoplastic epithelial cells, (×10, ×20, ×40 magnifications).
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Table 1 Clinicopathological variables as predictors of disease-specific survival in NSCLC patients
Total (%) 5-Year (%) Median (mo) HR (95%CI) P
Age .630
b65 227 (42) 57 134 1
≥65 310 (58) 58 144 0.94 (0.72–1.22)
Gender .040 a
Female 173 (32) 63 152 1
Male 364 (68) 55 133 1.35 (1.03–1.79)
Weight loss 1.000 a
b10% 483 (90) 58 138 1
N10% 53 (10) 59 148 1 (0.62–1.6)
Missing 1 (0)
Smoking .030 a
Never 19 (4) 50 117 1
Present 343 (64) 62 146 0.64 (0.31–1.35)
Previous 175 (33) 50 126 0.9 (0.42–1.93)
ECOG-PS .020 a
0 316 (59) 62 143 1
1 184 (34) 52 106 1.47 (1.1–1.96)
2 37 (7) 51 126 1.47 (0.78–2.76)
Histology .020 a
SCC 298 (55) 63 108 1
ADC 232 (43) 51 95 1.26 (0.97–1.65)
LCC 3 (1) 100 170 0 (0–0)
ASC 3 (1) 50 92 1.74 (0.15–20.22)
NOS 1 (0) 0 11 10.43 (0.03–4186.78)
Tstage b.001 a
T1a 14 (3) 93 186 1
T1b 70 (13) 80 179 1.33 (0.6–2.96)
T1c 92 (17) 63 134 3.21 (1.46–7.07)
T2a 132 (25) 57 125 3.79 (1.75–8.2)
T2b 72 (13) 47 107 4.84 (2.13–11)
T3 100 (19) 56 130 3.68 (1.67–8.13)
T4 57 (11) 26 71 8.81 (3.63–21.38)
Nstage b.001 a
N0 365 (68) 69 156 1
N1 117 (22) 37 83 2.74 (1.92–3.93)
N2 55 (10) 20 52 4.25 (2.45–7.36)
Pstage b.001 a
IA1 9 (2) 89 153 1
IA2 61 (11) 83 168 0.67 (0.25–1.77)
IA3 71 (13) 70 136 1.61 (0.61–4.26)
IB 85 (16) 69 136 1.52 (0.58–3.98)
IIA 45 (8) 59 118 2.1 (0.76–5.83)
IIB 136 (25) 59 112 2.3 (0.89–5.96)
IIIA 109 (20) 28 65 5.15 (1.93–13.72)
IIIB 21 (4) 0 20 10.03 (2.54–39.54)
Differentiation b b.001 a
Poor 230 (43) 48 120 1
Moderate 228 (42) 62 137 0.68 (0.51–0.91)
Well 79 (15) 73 190 0.38 (0.26–0.56)
Vascular invasion b.001 a
No 442 (82) 62 131 1
Yes 92 (17) 36 89 1.95 (1.31–2.89)
Missing 3 (1)
Abbreviations: ECOG-PS, Eastern Cooperative Oncology Group performance status; ADC, adenocarcinoma; SCC, squamous cell carcinoma; LCC, large cell
carcinoma; ASC, adenosquamous carcinoma; NOS, not otherwise specified; Nstage, nodal stage; Pstage, pathological stage; Tstage, tumor stage.
a Statistically significant
b Differentiation data is based on the 2004 World Health Organization (WHO) Classification of Lung Tumors.
191Tumor-infiltrating lymphocytes (TILs) in NSCLC
Table 2 Correlations between clinicopathological variables and TILs in resected tumor tissue from NSCLC patients
Tumor-infiltrating lymphocytes
0–5% 6%–25% 26%–50% N50% P
Total 52 270 167 48
Age .456
b65 22 121 62 19
≥65 30 149 105 29
Gender .099
Female 13 78 65 17
Male 39 192 102 31
Weight loss .648
b10% 46 239 153 45
N10% 6 30 14 3
Missing 1
Smoking .315
Never 3 11 5 0
Present 32 168 105 38
Previous 17 91 57 10
ECOG-PS .005 a
0 23 150 106 37
1 23 96 55 10
2 6 24 6 1
Histology .59
SCC 27 142 97 32
ADC 25 124 68 15
LCC 0 1 1 1
ASC 0 2 1 0
NOS 0 1 0 0
Tstage .080
T1a 0 8 1 5
T1b 8 32 23 7
T1c 8 39 40 5
T2a 15 70 35 12
T2b 6 33 26 7
T3 12 52 29 7
T4 3 36 13 5
Nstage .599
N0 31 189 113 32
N1 15 53 40 9
N2 6 28 14 7
Pstage .380
IA1 0 5 1 3
IA2 6 27 22 6
IA3 5 34 29 3
IB 7 51 20 7
IIA 4 18 17 6
IIB 18 65 42 11
IIIA 10 56 32 11
IIIB 2 14 4 1
Differentiation b .225
Poor 26 108 71 25
Moderate 21 117 69 21
Well 5 45 27 2
Vascular invasion .337
No 45 226 135 36
Yes 6 44 30 12
Missing 1 2
Abbreviations: ECOG-PS = Eastern Cooperative Oncology Group performance status, ADC = adenocarcinoma, SCC = squamous cell carcinoma, LCC = large-
cell carcinoma, ASC = adenosquamous carcinoma, NOS = not otherwise specified, Nstage = nodal stage, Pstage = pathological stage, Tstage = tumor stage.
a Statistically significant.
b Differentiation data is based on the 2004 World Health Organization (WHO) Classification of Lung Tumors.
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Fig. 2 Low to high level of stromal TILs in NSCLC on hematoxylin and eosin–stained sections. Infiltration scale (A) 0: 0-5%, (B) 1: 6%-25%,
(C) 2:26%-50% (D) 3: N50% (×10 and ×20 magnification, left and right column)





























































































































































































































































































































































































194 M. Rakaee et al.scattered pattern of TILs within the stroma; (2) TILs are more
often localized adjacent to neoplastic epithelial cells, and in
some stromal areas TILs form patchy lymphocytic aggregates;
(3) Highly dense infiltration of immune cells into the stroma.
In breast cancer this group has been termed lymphocyte-pre-
dominant breast cancer or LPBC [20,25].
The stromal areas and parameters excluded from assess-
ment were as follows: (1) Tumor associated stromal granulo-
cytes (TAGs): Neutrophils and eosinophils were excluded
(Fig. 1A and B). (2) Tertiary lymphoid structures (TLS): Fol-
licular lymphoid aggregates with a central germinal center lo-
cated in the stroma adjacent to tumor epithelium were
considered as TLS and excluded (Fig. 1C). In addition, distal
lymphoid aggregates without germinal center situated at the
invasive margin were ignored to assess (Fig. 1F). (3) Necrosis:
Intact tumor and intervening stromal tissue was evaluated in
full-tissue disregarding areas with crushing artifacts or necro-
sis (Fig. 1A). (4) Tumor border: TILs outside of the juxtatu-
moral stromal area, such as the invasive margin, were
ignored (Fig. 1E and F). (5) Normal lung tissue: TILs located
in normal lung tissue adjacent to the tumor were ineligible to
count (Fig. 1G).
2.3. Statistical procedures
Statistical analyses were performed using the R project
(version 3.2.2) for statistical computing. The associations be-
tween TILs presence and clinicopathological markers were
compared using either Chi-squared or Fisher's exact tests
whenever appropriate. For univariate analyses, the Kaplan–
Meier method was used to estimate survival curves and the
log-rank test was used to compare groups. Disease-specific
survival (DSS), disease-free survival (DFS) and overall sur-
vival (OS) were defined as the time from surgery to lung can-
cer death, to first lung cancer relapse, and to death of any
cause, respectively. Multivariate analyses were conducted
using Cox-regression models. All clinicopathological vari-
ables with P b .25 from the univariate analyses were entered
into the multivariate Cox regression analysis. The final multi-
variable models were selected through a supervised manual
approach. The significance level used was P b .05.3. Results
3.1. Clinicopathological characteristics
The 537 tumor specimens comprised 298 squamous cell
carcinomas (SCC), 232 adenocarcinomas (ADC), 3 large
cell carcinomas (LCC) and 3 adenosquamous carcinoma
(ASC) and 1 carcinoma NOS. The ADC patients were fur-
ther subtyped as follows: solid (n = 89), acinary (n = 80),
papillary (n = 42), micropapillary (n = 17) and mucinous
lepidic (n = 4). Distribution of patients according to the
UICC 8th TNM staging were: I (n = 226), II (n = 181),
Fig. 3 Survival curves for the overall cohort according to stromal TIL levels. (A) overall survival; (B) disease-specific survival; (C) disease-free
survival.
Table 4 Multivariable models summarizing significant independent prognostic factors for OS, DSS and DFS
OS DSS DFS
HR(95%CI) P HR(95%CI) P HR(95%CI) P
TILs
0–5% 1 1 1
6%–25% 0.76 (0.54–1.07) .114 0.69 (0.45–1.07) .096 0.66 (0.44–0.98) .041 a
26%–50% 0.65 (0.45–0.93) .019 a 0.63 (0.39–1) .050 a 0.62 (0.4–0.94) .026 a
N50% 0.51 (0.32–0.82) .006 a 0.3 (0.15–0.6) b.001 a 0.34 (0.19–0.64) b.001 a
Age 1.03 (1.02–1.04) b.001 a
Gender
Female 1 1
Male 1.36 (1.08–1.71) .008 a 1.31 (0.97–1.77) .076
Pstage
IA1 1 1 1
IA2 0.74 (0.29–1.93) .541 0.58 (0.12–2.7) .487 0.96 (0.22–4.25) .958
IA3 1.08 (0.43–2.73) .867 1.17 (0.27–4.99) .835 1.7 (0.4–7.16) .468
IB 1.22 (0.49–3.04) .676 1.08 (0.26–4.6) .913 1.7 (0.41–7.09) .469
IIA 1.61 (0.63–4.14) .319 1.54 (0.35–6.73) .566 2.05 (0.48–8.79) .335
IIB 1.23 (0.5–3.06) .648 1.6 (0.39–6.62) .515 2.18 (0.53–8.97) .278
IIIA 2.62 (1.06–6.48) .038 a 3.84 (0.93–15.84) .063 4.55 (1.11–18.7) .036 a
IIIB 5.16 (1.89–14.03) .001 a 6.49 (1.46–28.81) .014 a 8.12 (1.84–35.84) .006 a
Differentiation b
Poor 1 1
Moderate 0.88 (0.66–1.18) .396 0.87 (0.67–1.13) .31
Well 0.55 (0.33–0.9) .020 a 0.48 (0.3–0.76) .002 a
Vascular invasion
No 1 1 1
Yes 1.69 (1.29–2.2) b.001 a 1.72 (1.23–2.4) .001 a 1.41 (1.03–1.92) .030 a
Abbreviations: OS = overall survival, DSS = disease-specific survival, DFS = disease-free survival, HR = hazard ratio, CI = confidence interval, Pstage =
pathological stage.
a Statistically significant.
b Differentiation data is based on the 2004 World Health Organization (WHO) Classification of Lung Tumors.
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196 M. Rakaee et al.III (n = 130) (Table 1). For further analyses the cohort was di-
vided in four groups based on TIL level. There were no major
differences in clinicopathological characteristics between pa-
tients with high to minimal TIL levels in the overall cohort
(Table 2).
3.2. Interobserver validity
Scores from the observers were compared using a two-way
random effects model measuring absolute agreement of
values. The intraclass correlation coefficients (ICC) showed
an excellent agreement (ICC = 0.84, P b .001) between the ob-
servers (S.M.D, M.R).
3.3. TILs distribution
Lymphocyte infiltration was found within the tumors,
around the tumor (stromal) and at the tumor edges. Based on
the assessment criteria summarized in Supplementary Table
S1, the cohort was classified into four semi-quantitative cate-
gories according to TIL levels: score 0 (9%, 52 of 537), score
1 (49%, 270 of 537), score 2 (30%, 167 of 537), and score 3
(9%, 48 of 537). Example images of representative stromal
TIL scores are provided in Fig. 2A-D.
3.4. Survival analysis
The results of the univariate analyses are presented in Table
3 and Fig. 3. In the overall cohort, high TIL level was associ-
ated with improvedDSS (P = .008), DFS (P = .006) and OS (P
= .036). Five-year survival rates for high, moderate, mild and
minimal TILs score in the overall cohort were as follows:
OS: 59%, 50%, 41% and 34%; DSS: 77%, 63%, 54% and
42%; DFS: 73%, 56%, 48% and 33%, respectively.
Subgroup analyses showed that high TILs score was a pos-
itive prognostic factor for DSS (P = .047) and with a positive
trend observed for OS (P = .058) and DFS (P = .054) in the
SCC subgroup (Supplementary Fig. S2, A-C). No significant
association with survival was found for ADC patients (Supple-
mentary Fig. S2, D-F).
Table 4 summarizes the multivariable models for OS, DSS
and DFS in the overall cohort. High TIL levels were an inde-
pendent positive predictor of OS (HR 0.51 95% CI 0.32–
0.82, P = .006), DSS (HR 0.3 95% CI 0.15–0.6, P b .001)
and DFS (HR 0.34 95% CI 0.19–0.64, P b .001). In addition
to TILs level, pathological stage, histological differentiation,
vascular invasion, age and gender were significant indepen-
dent indicators for almost all endpoints.4. Discussion
Our group, and others, have previously demonstrated that
the presence of different TIL subsets (CD3, CD4, CD8,
CD20 and CD45RO) are associated with a marked survivaladvantage, independent of tumor stage, in NSCLC patients
[4-6]. The present study examined the prognostic relevance
of TILs in whole-tissue hematoxylin and eosin-stained (WT-
HE) slides of NSCLC surgical specimens, utilizing and vali-
dating a structured and reproducible evaluation method previ-
ously proposed for breast cancer patients. The findings
indicate that an increasing stromal TIL levels is an indepen-
dent positive prognosticator associated with a significantly
lower risk of progression, lower overall mortality and an im-
provedDSS inNSCLC patients. To the best of our knowledge,
this is the first large study to incorporate a well-defined scoring
instruction for reliable evaluation of TILs onWT-HE slides in
patients with lung cancer.
The prognostic influence of in situ immune cell infiltrates
in primary NSCLC was described decades ago, often in the
context of small cell carcinoma [26]. However, only a few
studies have used standard H&E stained slides instead of
IHC to evaluate lymphocyte infiltration in resected lung tissue
[15-19,27]. Survival benefit associated with high TIL density
was observed in three of the studies, in which patients cohort
were limited either to pathological stage I [17,18] or III [19].
Ruffini et al showed that TILs are more frequent in neuroendo-
crine tumors and positively associated with outcome in the
SCC subgroup, but not in the overall cohort [16]. In a large
TMA-based study, the presence of CD8+ cells was correlated
with an improved survival while TILs evaluated by H&E
failed to reach statistical significance [27]. In the present study,
stromal TILs were associated with DSS, OS and DFS (P =
.008, P = .03, P = .006 respectively) in the overall cohort. This
is in concordance with a large and recent NSCLC study by
Brambilla et al [15]. After stratification by histotype, a signif-
icant positive prognostic impact of TILs was observed in the
SCC subgroup (DSS: P = .047).
Despite solid evidence supporting the prognostic impact of
TIL density in NSCLC, a standardized scheme for WT-HE
TIL assessment has not been established. In this study, the rec-
ommendation for TIL evaluation in breast cancer [20] was
adapted for use on lung cancer tissue. To design a consistent
framework for assessing TILs, the following three components
were excluded: TILs within intratumoral areas, invasive mar-
gins, and TLS. (A) Intratumoral TILs: In breast cancer, Den-
kert et al [25] demonstrated that intratumoral TILs had both
a prognostic and predictive role. In lung cancer tissue, distin-
guishing lymphocytes and apoptotic tumor epithelial cells
proved challenging in some cases (Fig. 1H). Consequently,
intraepithelial TILs were considered unscorable. (B) TILs
within the invasive margins: In colorectal cancer (CRC), the
importance on the prognostic role of TILs within the invasive
margins has been highlighted [28,29]. For example, in hepatic
metastases of CRC, high density of CD8+ TILs in the invasive
margin predicts a better prognosis and response to chemother-
apy. In this study, the invasive margin was defined as an area
of 500 μm on each side of the edges between tumor epithelium
cells and normal tissue [29]. In our assessment, we were not
able to define a unique margin size for all patients. The inva-
sive margin around the tumor nest, for each NSCLC patient,
197Tumor-infiltrating lymphocytes (TILs) in NSCLChad a highly unstable pattern (Fig. 1E and F). Moreover, in
some specimens, small islands of neoplastic epithelium were
observed, making it hard or impossible to have a consistent
definition of the invasive margin. Due to these observations,
evaluation of TILs at the invasive margin may have low repro-
ducibility and should be excluded in the context of lung can-
cer. (C) TLS: It has been hypothesized that TLS has a
critical anti-tumoral role by induction of a systemic and local
T-cell immune response, and TLS have been observed in al-
most all solid tumors including NSCLC [30]. In lung cancer,
the density of mature dendritic cells within TLS was associ-
ated with a favorable outcome [31]. Architecturally, TLS are
very similar to lymph nodes composed of T-cell–DC clusters,
follicular B cells and specialized vessels known as high endo-
thelial venules. Due to the profound presence of immune cells
in TLSs and to avoid false positive count, TLS were not in-
cluded in this setting.
In subgroup analysis according to TNM stage, TIL levels
was a near significant prognostic factor for stage II and III pa-
tients and a trend could be observed for stage I patients (Sup-
plementary Fig. S3). However, previous studies have observed
that a high density of TILs also predicts extended overall sur-
vival at earlier stages of disease. Both Ruffini and Horne et al
(1290 and 273 patients, respectively) indicated a survival ad-
vantage associated with TIL levels in NSCLC stage I
[16,17]. In our study, the positive prognostic effect was not
statistically significant in stage I for all endpoints, consistent
with previous reports in early-stage breast, esophageal and co-
lorectal cancers [32-34]. It appears that TIL level may have a
stronger prognostic role for patients with a more aggressive
NSCLC phenotype. Nevertheless, these results should be
interpreted cautiously and a study powered for subgroup anal-
yses might shed more light on our data, especially for stage I
patients. Moreover, as we have previously proposed for stro-
mal CD8 [5], intratumoral CD45RO [6] and the combination
of stromal PD-L1 and intratumoral PD-1 [7] in NSCLC, which
predicted outcome independently of other variables and within
each pathological stage, WT-HE TILs appear to be a promis-
ing candidate marker to supplement NSCLC TNM-I with re-
spect to prognosis and stratification for adjuvant therapy.
Further, our research group is presently conducting a prospec-
tive Scandinavian study (NCT03299478) to validate a NSCLC
TNM-I as a prognostic tool in the post-surgical treatment set-
ting. Evaluation of WT-HE TILs may be integrated into this
trial.
The novelty of the present study is primarily the demonstra-
tion that increasing TIL levels in the tumor stroma were asso-
ciated with prognostic information. All the statistical analyses
were conducted with a four-category discrete cutoff value. In
contrast, Feng et al [19] were not able to detect any prognostic
impact of TILs after implementation of a four-step method.
We believe that an easy-to-use grading scheme, as suggested
in this study, will reduce confusion and avert interobserver re-
producibility problems, and provide enhanced prognostic ac-
curacy for TILs in NSCLC. Although the evaluation of TILs
is lucid, promising, inexpensive, and can be easily introducedinto routine histopathology reporting, it remains a semi-quan-
titative marker and requires further validation utilizing a com-
puter-based cell counter.5. Conclusions
This study identifies a stepwise increase in stromal TIL
levels, assessed onWT-HE slides, to be an independent, favor-
able prognostic factor in a cohort of resectable stage I-III
NSCLC patients. When deciding which TIL identifier to in-
clude in a NSCLC TNM-I, the exhaustive morphological
TIL assessment using WT-HE slides proposed in this study,
may be a favorable choice due to ease of implementation and
low cost.Supplementary data
Supplementary data to this article can be found online at
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Figure S1: Schematic model showing NSCLC tissue with the area used for evaluation of 
TILs. The most advanced edge of the tumor was considered as tumor border or invasive 
margin and excluded from assessment. 
 
 
Figure S2: Survival curves according to TIL levels representing OS, DSS and DFS in the 
SCC (A-C) and ADC (D-F) subgroups, respectively. 





Figure S3: Survival curves for OS (A-C), DSS (E-G) and DFS (I-J) and distribution of 
patients with similar D) OS; H) DSS; L) DFS, according to pathological stage and TIL levels 
in the overall cohort (good prognosis: light green; intermediate prognosis: dark green; poor 
prognosis: orange; very poor prognosis: red). These illustrations highlight how TIL levels 
may be used to calibrate the current TNM staging system. 




Table S1: Scoring assessment criteria; A) Scoring scale and morphological characteristics of 
TILs in tumor stroma, B) Parameters excluded in the evaluation. 
A 
Score TIL % Stroma configuration 
0 0-5% very rare immune cells, almost no cell 
1 6-25% loose, scattered immune infiltration 
2 26-50% patchy aggregates of mononuclear inflammatory cells 









TAG: TAN, TAE 
TAM 
Adjacent/distal follicular lymphoid aggregates: TLS  
 
Abbreviations: TILs=tumor-infiltrating lymphocytes, TAG=tumor-associated granulocytes, TAN= tumor-
associated neutrophils, TAE= tumor associated-eosinophils, TAM= Tumor-associated macrophages, TLS= 
tertiary lymphoid structure 
 
